Sean Emery

Senior Vice Dean (Research and Operations)
Deputy Director

Research Interests:
The evaluation of new treatments, new treatment strategies and biomedical preventive measures for HIV infection. The design and implementation of clinical research programs and projects to generate quality evidence to advise healthcare providers and policy makers. To balance high tech medicine with the reality of limited resources in countries where needs are greatest.

Broad Research Areas:
Clinical Research, HIV - AIDS, Immunology, Virology, Biostatistics

Qualifications:
BSc, PhD Brunel

Society Memberships & Professional Activities:
International AIDS Society (IAS), , Association of Regulatory and Clinical Scientists to the Australian Pharmaceutical Industry (ARCS)

Specific Research Keywords:
Acquired Immune Deficiency Syndrome (AIDS), Anti-viral Immunity, Biostatistics, Blood borne viruses, Clinical Research

 

Journal articles
add
Boatman JA; Baker JV; Emery S; Furrer H; Mushatt DM; Sedláček D; Lundgren JD; Neaton JD, 2019, 'Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression among Participants Initiating Antiretroviral Treatment with CD4+ Counts > 500 Cells/mm3: Findings from the Strategic Timing of AntiRetroviral Therapy (START) Trial', Journal of Acquired Immune Deficiency Syndromes, vol. 81, pp. 10 - 17, http://dx.doi.org/10.1097/QAI.0000000000001967
2019
Singkham N; Avihingsanon A; Thammajaruk N; Ruxrungtham K; Bunupuradah T; Kiertiburanakul S; Chetchotisakd P; Burger DM; Emery S; Punyawudho B, 2019, 'Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients', Pharmacogenomics, vol. 20, pp. 517 - 527, http://dx.doi.org/10.2217/pgs-2018-0196
2019
Borges ÁH; Neuhaus J; Sharma S; Neaton JD; Henry K; Anagnostou O; Staub T; Emery S; Lundgren JD, 2019, 'The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis', Journal of Infectious Diseases, vol. 219, pp. 254 - 263, http://dx.doi.org/10.1093/infdis/jiy442
2019
Sereti I; Gulick RM; Krishnan S; Migueles SA; Palfreeman A; Touzeau-Römer V; Belloso WH; Emery S; Law MG, 2019, 'ART in HIV-Positive Persons with Low Pretreatment Viremia: Results from the START Trial', Journal of Acquired Immune Deficiency Syndromes, vol. 81, pp. 456 - 462, http://dx.doi.org/10.1097/QAI.0000000000002052
2019
Lampe FC; Rodger AJ; Burman W; Grulich A; Friedland G; Sadr WE; Neaton J; Corbelli GM; Emery S; Molina JM; Orkin C; Gatell J; Gerstoft J; Ruxrungtham K; Barbosa De Souza M; Phillips AN, 2019, 'Impact of early antiretroviral treatment on sexual behaviour: A randomised comparison', AIDS, vol. 33, pp. 2337 - 2350, http://dx.doi.org/10.1097/QAD.0000000000002359
2019
Dharan NJ; Neuhaus J; Rockstroh JK; Peters L; Gordin F; Arenas-Pinto A; Emerson C; Marks K; Hidalgo J; Sarmento-Castro R; Stephan C; Kumarasamy N; Emery S; Matthews GV, 2019, 'Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial', Hepatology, vol. 69, pp. 1135 - 1150, http://dx.doi.org/10.1002/hep.30296
2019
Kent SJ; Hough S; Kelleher AD; Law MG; Hutchinson J; Catalfarmo M; van Bockel D; Lane C; Baker JV; Emery S, 2018, 'Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial', The Lancet HIV, vol. 5, pp. e553 - e559, http://dx.doi.org/10.1016/S2352-3018(18)30214-5
2018
Philpot SP; Prestage G; Ellard J; Grulich AE; Bavinton BR, 2018, 'How do gay serodiscordant couples in Sydney, Australia negotiate undetectable viral load for HIV prevention?', AIDS and Behavior, vol. 22, pp. 3981 - 3990, http://dx.doi.org/10.1007/s10461-018-2247-6
2018
Bavinton BR; Pinto AN; Phanuphak N; Grinsztejn B; Prestage GP; Zablotska-Manos IB; Jin F; Fairley CK; Moore R; Roth N; Bloch M; Pell C; McNulty AM; Baker D; Hoy J; Tee BK; Templeton DJ; Cooper DA; Emery S; Kelleher A; Grulich AE; Jin F; Bavinton BR; Cooper DA; Fairley CK; Wilson D; Koelsch KK; Triffitt K; Doong N; Baker D; McNulty A; Pell C; Hoy J; Tee BK; Moore R; Orth D; Pinto AN, 2018, 'Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study', The Lancet HIV, vol. 5, pp. e438 - e447, http://dx.doi.org/10.1016/S2352-3018(18)30132-2
2018
Trevillyan JM; Wong G; Puls R; Petoumenos K; Emery S; Mellett NA; Mundra PA; Meikle PJ; Hoy JF, 2018, 'Changes in plasma lipidome following initiation of antiretroviral therapy', PLoS ONE, vol. 13, http://dx.doi.org/10.1371/journal.pone.0202944
2018
Pett SL; Kunisaki KM; Wentworth D; Griffin TJ; Kalomenidis I; Nahra R; Sanchez RM; Hodgson SW; Ruxrungtham K; Dwyer D; Davey RT; Wendt CH; Lundgren J; Jansson P; Pearson M; Aagaard B; Hudson F; Bennet R; Pacciarini F; Angus B; Paton N; Collaco Moraes Y; Cooper D; Emery S; Courtney-Rogers D; Robson R; Gordin F; Sanchez A; Standridge B; Vjecha M; Moricz A; Delfino M; Belloso W; Losso M; Tillmann K; Touloumi G; Gioukari V; Anagnostou O; La Rosa A; Saenz MJ; Lopez P; Herrero P; Portas B; Kaewon P; Ubolyam S; Brekke K; Campbell M; Denning E; DuChene A; Engen N; George M; Harrison M; Neaton JD; Nelson R; Quan SF; Schultz T; Baxter J; Brown S; Hoover M; Beigel J; Dewar R; Gover E; McConnell R; Metcalf J; Natarajan V; Rehman T; Voell J; Dwyer DE; Kok J; Uyeki T; Munroe D; Paez A; Bertrand M; Temesgen Z; Rizza S; Wolfe C; Carbonneau J; Novak R; Schwarber M; Polenakovik H; Clark L; Patil N; Riska P; Omotosho J; Faber L; Markowitz N; Glesby M; Ham K; Parenti D; Simon G; Coburn P; Freiberg M; Koerbel G; Dharan N; Paez-Quinde M; Gunter J; Beilke M; Lu Z; Gunderson E; Baker J, 2018, 'Increased indoleamine-2,3-dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study', Open Forum Infectious Diseases, vol. 5, http://dx.doi.org/10.1093/ofid/ofx228
2018
Yao AH; Moore CL; Lim PL; Molina JM; Madero JS; Kerr S; Mallon PWG; Emery S; Cooper DA; Boyd MA, 2018, 'Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial', Antiviral Therapy, vol. 23, pp. 21 - 32, http://dx.doi.org/10.3851/IMP3171
2018
Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Alberto Arnaiz J; Cooper D; Rockstroh JK; Mallon P; Emery S; Fisher M; Rockstroh J; Stellbrink J; Merlin K; Yeung J; Fsadni B; Marks K; Suzuki K; Rismanto N; Salomon H; Rubio AE; Chibo D; Birch C; Swenson L; Chan D; Berg T; Obermeier M; Schuelter E; Aragon SS; Luebke N; Coughlan S; Dean J; Iwatani Y; Teran GR; Avila S; Sirivichayakul S; Naphassanant M; Ubolyam S; Kaye S; Land S; Walker S; Haubrich R; DeJesus E; Berthon-Jones N; Espinosa N; Courtney-Vega K; Absar N; Haskelberg H; Robson R; Donaldson A; Guelman D; Gambardella L; Valdovinos M; Arnaiz J; Beleta H; Ramos N; Targa M; Späth B; Boesecke C; Engelhardt A; Perry N; Beckthold B; Drummond F; Lefevre E; Corr S; Grant C; Lupo S; Peroni L; Sanchez M; De Paz Sierra M; Viloria G; Parlante A; Bissio E; Luchetti P; Confalonieri V; Warley E; Vieni I; Vilas C; Zarate A; Mayer G; Elliot J; Hagenauer M; Kelley M, 2018, 'Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study', HIV Medicine, vol. 19, pp. 65 - 71, http://dx.doi.org/10.1111/hiv.12532
2018
Peterson RL; Vock DM; Powers JH; Emery S; Cruz EF; Hunsberger S; Jain MK; Pett S; Neaton JD, 2017, 'Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization', Clinical Trials, vol. 14, pp. 264 - 276, http://dx.doi.org/10.1177/1740774517697919
2017
Baker JV; Sharma S; Grund B; Rupert A; Metcalf JA; Schechter M; Munderi P; Aho I; Emery S; Babiker A; Phillips A; Lundgren JD; Neaton JD; Lane HC, 2017, 'Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial', OPEN FORUM INFECTIOUS DISEASES, vol. 4, http://dx.doi.org/10.1093/ofid/ofx262
2017
Murray DD; Suzuki K; Law M; Trebicka J; Neuhaus Nordwall J; Johnson M; Vjecha MJ; Kelleher AD; Emery S, 2017, 'Circulating MIR-122 and MIR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals', Scientific Reports, vol. 7, http://dx.doi.org/10.1038/s41598-017-11405-8
2017
Lee WS; Kristensen AB; Rasmussen TA; Tolstrup M; Østergaard L; Søgaard OS; Wines BD; Mark Hogarth P; Reynaldi A; Davenport MP; Emery S; Amin J; Cooper DA; Kan VL; Fox J; Gruell H; Parsons MS; Kent SJ, 2017, 'Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption', Journal of Virology, vol. 91, http://dx.doi.org/10.1128/JVI.00603-17
2017
Murray JM; Zaunders J; Emery S; Cooper DA; Hey-Nguyen WJ; Koelsch KK; Kelleher AD, 2017, 'HIV dynamics linked to memory CD4+ T cell homeostasis', PLoS ONE, vol. 12, http://dx.doi.org/10.1371/journal.pone.0186101
2017
Madhavi V; Kulkarni A; Shete A; Lee WS; McLean MR; Kristensen AB; Ghate M; Wines BD; Hogarth PM; Parsons MS; Kelleher A; Cooper DA; Amin J; Emery S; Thakar M; Kent SJ, 2017, 'Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts', Journal of Acquired Immune Deficiency Syndromes, vol. 75, pp. 345 - 353, http://dx.doi.org/10.1097/QAI.0000000000001380
2017
Boyd MA; Amin J; Mallon PWG; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA, 2017, 'Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study', The Lancet HIV, vol. 4, pp. e13 - e20, http://dx.doi.org/10.1016/S2352-3018(16)30189-8
2017
Dwyer DE; Lynfield R; Losso MH; Davey RT; Cozzi-Lepri A; Wentworth D; Uyeki TM; Gordin F; Angus B; Qvist T; Emery S; Lundgren J; Neaton JD, 2017, 'Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015', OPEN FORUM INFECTIOUS DISEASES, vol. 4, http://dx.doi.org/10.1093/ofid/ofx212
2017
Amara AB; Else LJ; Carey D; Khoo S; Back DJ; Amin J; Emery S; Puls RL, 2017, 'Comparison of dried blood spots versus conventional plasma collection for the characterization of efavirenz pharmacokinetics in a large-scale global clinical trial-the ENCORE1 study', Therapeutic Drug Monitoring, vol. 39, pp. 654 - 658, http://dx.doi.org/10.1097/FTD.0000000000000448
2017
Baker JV; Sharma S; Achhra AC; Bernardino JI; Bogner JR; Duprez D; Emery S; Gazzard B; Gordin J; Grandits G; Phillips AN; Schwarze S; Soliman EZ; Spector SA; Tambussi G; Lundgren J, 2017, 'Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial', Journal of the American Heart Association, vol. 6, http://dx.doi.org/10.1161/JAHA.116.004987
2017
Madhavi V; Wines BD; Amin J; Emery S; Lopez E; Kelleher A; Center RJ; Mark Hogarth P; Chung AW; Kent SJ; Stratov I, 2017, 'HIV-1 Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV', Journal of Virology, vol. 91, http://dx.doi.org/10.1128/JVI.00700-17
2017
Lifson AR; Grund B; Gardner EM; Kaplan R; Denning E; Engen N; Carey CL; Chen F; Dao S; Florence E; Sanz J; Emery S, 2017, 'Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection', AIDS, vol. 31, pp. 953 - 963, http://dx.doi.org/10.1097/QAD.0000000000001417
2017
Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R, 2016, 'Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study', Clinical Pharmacokinetics, vol. 55, pp. 861 - 873, http://dx.doi.org/10.1007/s40262-015-0360-5
2016
Revell A; Khabo P; Ledwaba L; Emery S; Wang D; Wood R; Morrow C; Tempelman H; Hamers RL; Reiss P; van Sighem A; Pozniak A; Montaner J; Lane HC; Larder B, 2016, 'Computational models as predictors of HIV treatment outcomes for the Phidisa cohort in South Africa', SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE, vol. 17, http://dx.doi.org/10.4102/sajhivmed.v17i1.450
2016
Revell AD; Wang D; Wood R; Morrow C; Tempelman H; Hamers RL; Reiss P; van Sighem AI; Nelson M; Montaner JSG; Lane HC; Larder BA; Harrigan R; de Wit TR; Hamers R; Sigaloff K; Agan B; Marconi V; Wegner S; Sugiura W; Zazzi M; Kaiser R; Schuelter E; Streinu-Cercel A; Alvarez-Uria G; Gatell J; Lazzari E; Gazzard B; Pozniak A; Mandalia S; Webster D; Smith C; Ruiz L; Clotet B; Staszewski S; Torti C; Lane C; Metcalf J; Perez-Elias MJ; Vella S; Dettorre G; Carr A; Norris R; Hesse K; Vlahakis E; Barth R; Hoffmann C; Ene L; Dragovic G; Diaz R; Sucupira C; Sued O; Cesar C; Madero JS; Emery S; Cooper D; Baxter J; Monno L; Picchio G; deBethune MP; Khabo P; Ledwaba L, 2016, 'An update to the HIV-TRePS system: The development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype', Journal of Antimicrobial Chemotherapy, vol. 71, pp. 2928 - 2937, http://dx.doi.org/10.1093/jac/dkw217
2016
Lam EP; Moore CL; Gotuzzo E; Nwizu C; Kamarulzaman A; Chetchotisakd P; Van Wyk J; Teppler H; Kumarasamy N; Molina JM; Emery S; Cooper DA; Boyd MA, 2016, 'Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE study', AIDS Research and Human Retroviruses, vol. 32, pp. 841 - 850, http://dx.doi.org/10.1089/aid.2015.0331
2016
Kunisaki KM; Niewoehner DE; Collins G; Aagaard B; Atako NB; Bakowska E; Clarke A; Corbelli GM; Ekong E; Emery S; Finley EB; Florence E; Infante RM; Kityo CM; Madero JS; Nixon DE; Tedaldi E; Vestbo J; Wood R; Connett JE, 2016, 'Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial', The Lancet Respiratory Medicine, vol. 4, pp. 980 - 989, http://dx.doi.org/10.1016/S2213-2600(16)30319-8
2016
Baker JV; Hullsiek KH; Engen NW; Nelson R; Chetchotisakd P; Gerstoft J; Jessen H; Losso M; Markowitz N; Munderi P; Papadopoulos A; Shuter J; Rappoport C; Pearson MT; Finley E; Babiker A; Emery S; Duprez D; Aagaard B; Borges H; Jansson PO; Neilsen BR; Arenas-Pinto A; Atako NB; Babiker AG; Dennis E; Forcat S; Hudson F; Jackson B; Maas D; Purvis C; Russell C; Carey C; Clewett M; Jacoby S; Finley EB; Sánchez A; Vjecha MJ, 2016, 'Early antiretroviral therapy at high CD4 counts does not improve arterial elasticity: A substudy of the strategic timing of antiretroviral treatment (START) trial', Open Forum Infectious Diseases, vol. 3, http://dx.doi.org/10.1093/ofid/ofw213
2016
Klassen KM; Kimlin MG; Fairley CK; Emery S; Anderson PH; Ebeling PR, 2016, 'Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV', Osteoporosis International, vol. 27, pp. 1737 - 1745, http://dx.doi.org/10.1007/s00198-015-3432-3
2016
Bunupuradah T; Kiertiburanakul S; Avihingsanon A; Chetchotisakd P; Techapornroong M; Leerattanapetch N; Kantipong P; Bowonwatanuwong C; Banchongkit S; Klinbuayaem V; Mekviwattanawong S; Nimitvilai S; Jirajariyavej S; Prasithsirikul W; Munsakul W; Bhakeecheep S; Chaivooth S; Phanuphak P; Cooper DA; Apornpong T; Kerr SJ; Emery S; Ruxrungtham K, 2016, 'Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial', The Lancet HIV, vol. 3, pp. e343 - e350, http://dx.doi.org/10.1016/S2352-3018(16)30010-8
2016
Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S, 2016, 'Maraviroc, as a switch option, in HIV-1-infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first Nucleoside/Nucleotide reverse transcriptase inhibitor plus ritonavir-boosted protease inhibitor regimen: Week 48 Results of the randomized, multicenter March study', Clinical Infectious Diseases, vol. 63, pp. 122 - 132, http://dx.doi.org/10.1093/cid/ciw207
2016
Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H; Renjifo B; Molina JM; Emery S; Cooper DA, 2015, 'Erratum: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (PLoS ONE (2015)10:2 (e0118228) Doi: 10.1371/journal.pone.0118228 ))', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0140623
2015
Sharma S; Babiker A; Emery S; Gordin F; Lundgren J; Neaton J; Bakowska E; Schechter M; Wiselka M; Wolff M, 2015, 'Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial', HIV Medicine, vol. 16, pp. 30 - 36, http://dx.doi.org/10.1111/hiv.12231
2015
Winston A; Puls R; Kerr SJ; Duncombe C; Li P; Gill JM; Ramautarsing R; Taylor-Robinson SD; Emery S; Cooper DA; Belloso W; Gazzard B; Hung CC; Jessen H; Kamrulazaman A; Li L; Losso M; Sierra-Madero J; Mallon P; Mason B; Molina JM; Petoumenos K; Phanuphak P; Pollack S; Rooney J; Walmsley S; Wolff M, 2015, 'Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0118608
2015
Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H; Renjifo B; Molina JM; Emery S; Cooper DA, 2015, 'Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: A randomised open label study for the treatment of HIV-1 infection', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0118228
2015
Hey-Cunningham WJ; Murray JM; Natarajan V; Amin J; Moore CL; Emery S; Cooper DA; Zaunders J; Kelleher AD; Koelsch KK; PINT study team , 2015, 'Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.', AIDS, vol. 29, pp. 911 - 919, http://dx.doi.org/10.1097/QAD.0000000000000625
2015
Winston A; Amin J; Clarke A; Else L; Amara A; Owen A; Barber T; Jessen H; Avinghsanon A; Chetchotisakd P; Khoo S; Cooper DA; Emery S; Puls R, 2015, 'Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: A randomized controlled trial', Clinical Infectious Diseases, vol. 60, pp. 1026 - 1032, http://dx.doi.org/10.1093/cid/ciu976
2015
Achhra AC; Phillips A; Emery S; Macarthur RD; Furrer H; De Wit S; Losso M; Law MG, 2015, 'Pre-therapy inflammation and coagulation activation and long-term CD4 count responses to the initiation of antiretroviral therapy', HIV Medicine, vol. 16, pp. 449 - 454, http://dx.doi.org/10.1111/hiv.12258
2015
Berthon-Jones N; Courtney-Vega K; Donaldson A; Haskelberg H; Emery S; Puls R, 2015, 'Assessing site performance in the Altair study, a multinational clinical trial', Trials, vol. 16, http://dx.doi.org/10.1186/s13063-015-0653-x
2015
Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Foulkes S; Hill A; Jessen H; Kumar S; Lee MP; Nwizu C; Read T; Rooney J; Schaffer K; Shahar E; Winston A; Wolff M; Young B; Abela C; Avihingsanon A; Boyd M; Carey D; Clarke A; Courtney-Vega K; Delfino M; Donaldson A; Emery S; Espinosa N; Johannesen T; Lin E; Losso M; Moricz A; Pett S; Phanupak P; Puls R; Pussadee K; Sutheerasak P; Tomlins L; Ubolyam S; bin Raja Azwa RIS; Bissio E; Calanni L; Chetchotisakd P; Doong N; Elliott J; Gazzard B; Kelly M; Laplume H; del Carmen Luna N; Lupo S; Messina OG; Mohapi L; Moore R; Nolan D; Orrell C; Perez C; Phanuphak P; Rockstroh J; Rowling D; Supparatpinyo K; Smith D; Villanueva JA; Vlahakis E; Kelleher T; Cunningham P; Merlin K; Yeung J; Shaik A; Fsadni B; Carrera A; Lograsso M; Gulick R; Dunn D; Dolan M, 2015, 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study', The Lancet Infectious Diseases, vol. 15, pp. 793 - 802, http://dx.doi.org/10.1016/S1473-3099(15)70060-5
2015
Soliman E; Sharma S; Arastéh K; Wohl D; Achhra A; Tambussi G; O'Connor J; Stein J; Duprez D; Neaton J; Phillips A, 2015, 'Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial', HIV Medicine, vol. 16, pp. 46 - 54, http://dx.doi.org/10.1111/hiv.12233
2015
Lundgren JD; Babiker AG; Gordin F; Emery S; Grund B; Sharma S; Avihingsanon A; Cooper DA; Fätkenheuer G; Llibre JM; Molina JM; Munderi P; Schechter M; Wood R; Klingman KL; Collins S; Clifford Lane H; Phillips AN; Neaton JD, 2015, 'Initiation of antiretroviral therapy in early asymptomatic HIV infection', New England Journal of Medicine, vol. 373, pp. 795 - 807, http://dx.doi.org/10.1056/NEJMoa1506816
2015
McFadden E; Bashir S; Canham S; Darbyshire J; Davidson P; Day S; Emery S; Pater J; Rudkin S; Stead M; Brown J, 2015, 'The impact of registration of clinical trials units: The UK experience', Clinical Trials, vol. 12, pp. 166 - 173, http://dx.doi.org/10.1177/1740774514561242
2015
Borges ÁH; O'Connor JL; Phillips AN; Rönsholt FF; Pett S; Vjecha MJ; French MA; Lundgren JD, 2015, 'Factors Associated with Plasma IL-6 Levels during HIV Infection', Journal of Infectious Diseases, vol. 212, pp. 585 - 595, http://dx.doi.org/10.1093/infdis/jiv123
2015
Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R, 2015, 'Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study', Clinical Pharmacology and Therapeutics, vol. 98, pp. 406 - 416, http://dx.doi.org/10.1002/cpt.156
2015
Lundgren J; Babiker A; Gordin F; Emery S; Fätkenheuer G; Molina JM; Wood R; Neaton JD; Agan BK; Alston-Smith B; Arenas-Pinto A; Arribas JR; Baker JV; Baxter J; Belloso WH; Brekke K; Brew B; Brobst SW; Burman W; Carey C; Clark R; Cooper DA; Davey RT; De La Rosa G; Denning ET; Dolan M; Dore G; Duprez D; Emanuel E; Grady C; Grund B; Hirschel B; Hoen B; Hudson F; Johnson MA; Kambili C; Klingman K; Kunisaki KM; Landay A; Ledergerber B; Lehrman SN; Martinez A; Meger S; Misar K; Mitsuyasu RT; Mocroft A; Munroe D; Norton M; Palmer RC; Pett SL; Phillips A; Pillay D; Porter D; Price RW; Proschan M; Rappoport C; Reiss P; Renjifo B; Robertson K; Rockstroh J; Rodriguez G; Rooney JF; Ross MJ; Schechter M; Schwarze S; Seekins D; Sharma S; Snowden W; Telenti A; Tryon J; van Wyk J; Vjecha MJ; Wright E, 2015, 'Why START? Reflections that led to the conduct of this large long-term strategic HIV trial', HIV Medicine, vol. 16, pp. 1 - 9, http://dx.doi.org/10.1111/hiv.12227
2015
Murray DD; Suzuki K; Law M; Trebicka J; Neuhaus J; Wentworth D; Johnson M; Vjecha MJ; Kelleher AD; Emery S; Aagaard B; Aragon E; Arnaiz J; Borup L; Clotet B; Dragsted U; Fau A; Gey D; Grarup J; Hengge U; Herrero P; Jansson P; Jensen B; Jensen K; Juncher H; Lopez P; Lundgren JD; Matthews C; Mollerup D; Pearson M; Phillips A; Reilev S; Tillmann K; Varea S; Angus B; Babiker A; Cordwell B; Darbyshire J; Dodds W; Fleck S; Horton J; Hudson F; Moraes Y; Pacciarini F; Palfreeman A; Paton N; Smith N; Van Hooff F; Bebchuk J; Collins G; Denning E; DuChene A; Fosdick L; Harrison M; Herman-Lamin K; Krum E; Larson G; Neaton J; Nelson R; Quan K; Quan S; Schultz T; Thompson G; Wyman N; Carey C; Chan F; Cooper D; Courtney-Rodgers D; Drummond F; Harrod M; Jacoby S; Kearney L; Lin E; Pett S; Robson R; Seneviratne N; Stewart M; Watts E; Finley E; Gordin F; Sánchez A; Standridge B; Belloso W; Davey R; Duprez D; Gatell J; Hoy J; Lifson A; Pederson C; Perez G; Price R; Prineas R; Rhame F; Sampson J; Worley J; Modlin J; Beral V; Chaisson R; Fleming T; Hill C, 2015, 'Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0139981
2015
Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA, 2015, 'Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis', The Lancet HIV, vol. 2, pp. e42 - e51, http://dx.doi.org/10.1016/S2352-3018(14)00061-7
2015
Amin J; Law MG; Puls R; Kelleher A; Cooper DA; Emery S, 2014, 'Comparison of central and local HIV-1 RNA quantification from two international clinical trials', AIDS, vol. 28, pp. 2480 - 2483, http://dx.doi.org/10.1097/QAD.0000000000000461
2014
Dooko CBA; De Wit S; Neuhaus J; Palfreeman A; Pepe R; Pankow JS; Neaton JD, 2014, 'Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy', Journal of Acquired Immune Deficiency Syndromes, vol. 67, pp. 538 - 546
2014
Haskelberg H; Pocock N; Amin J; Ebeling PR; Emery S; Carr A, 2014, 'Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0094858
2014
Dawood FZ; Roediger MP; Grandits G; Miller D; Fisher M; Zhang ZM; Hodder S; Hoy JF; Lundgren JD; Neaton JD; Soliman EZ, 2014, 'Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: Results from the Strategies for Management of Antiretroviral Therapy [SMART] Study', Journal of Electrocardiology, vol. 47, pp. 264 - 271, http://dx.doi.org/10.1016/j.jelectrocard.2013.12.001
2014
Haskelberg H; Cordery DV; Amin J; Kelleher AD; Cooper DA; Emery S, 2014, 'HLA Alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0093333
2014
Miller CJ; Baker JV; Bormann AM; Erlandson KM; Hullsiek KH; Justice AC; Neuhaus J; Paredes R; Petoumenos K; Wentworth D; Winston A; Wolfson J; Neaton JD, 2014, 'Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0095061
2014
Revell AD; Boyd MA; Wang D; Emery S; Gazzard B; Reiss P; van Sighem A; Montaner JS; Lane HC; Larder BA, 2014, 'A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy', HIV Medicine, vol. 15, pp. 442 - 448, http://dx.doi.org/10.1111/hiv.12156
2014
Nordell AD; McKenna M; Borges AH; Duprez D; Neuhaus J; Neaton JD, 2014, 'Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation', JOURNAL OF THE AMERICAN HEART ASSOCIATION, vol. 3, http://dx.doi.org/10.1161/JAHA.114.000844
2014
Haskelberg H; Mallon PWG; Hoy J; Amin J; Moore C; Phanuphak P; Ferret S; Belloso WH; Boyd MA; Cooper DA; Emery S, 2014, 'Bone mineral density over 96 weeks in adults failing first-line therapy randomised to raltegravir/lopinavir/ritonavir compared to standard second-line therapy', Journal of Acquired Immune Deficiency Syndromes, http://dx.doi.org/10.1097/QAI.0000000000000288
2014
Revell AD; Wang D; Wood R; Morrow C; Tempelman H; Hamers R; Alvarez-Uria G; Streinu-Cercel A; Ene L; Wensing A; Reiss P; van Sighem AI; Nelson M; Emery S; Montaner JSG; Lane HC; Larder BA; Reiss P; van Sighem A; Montaner J; Harrigan R; Rinke de Wit T; Hamers R; Sigaloff K; Agan B; Marconi V; Wegner S; Sugiura W; Zazzi M; Streinu-Cercel A; Alvarez-Uria G; Gatell J; Lazzari E; Gazzard B; Nelson M; Pozniak A; Mandalia S; Ruiz L; Clotet B; Staszewski S; Torti C; Lane C; Metcalf J; Perez-Elias M-J; Carr A; Norris R; Hesse K; Vlahakis E; Tempelman H; Barth R; Morrow C; Wood R; Ene L; Dragovic G; Cooper D; Torti C; Baxter J; Monno L; Torti C; Gatell J; Clotet B; Picchio G; deBethune M-P; Perez-Elias M-J, 2014, 'An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes', Journal of Antimicrobial Chemotherapy, vol. 69, pp. 1104 - 1110, http://dx.doi.org/10.1093/jac/dkt447
2014
Lynfield R; Davey R; Dwyer DE; Losso MH; Wentworth D; Cozzi-Lepri A; Herman-Lamin K; Cholewinska G; David D; Kuetter S; Ternesgen Z; Uyeki TM; Lane HC; Lundgren J; Neaton JD, 2014, 'Outcomes of influenza A(H1N1)pdm09 virus infection: Results from two international cohort studies', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0101785
2014
Haskelberg H; Mallon PWG; Hoy J; Amin J; Moore C; Phanuphak P; Ferret S; Belloso WH; Boyd MA; Cooper DA; Emery S, 2014, 'Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ ritonavir compared with standard second-line therapy', Journal of Acquired Immune Deficiency Syndromes, vol. 67, pp. 161 - 168, http://dx.doi.org/10.1097/QAI.0000000000000288
2014
Peters L; Neuhaus J; Duprez D; Neaton JD; Tracy R; Klein MB; Mocroft A; Rockstroh J; Dore G; Lundgren JD, 2014, 'Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study', Journal of Clinical Virology, vol. 60, pp. 295 - 300, http://dx.doi.org/10.1016/j.jcv.2014.03.017
2014
Lucas GM; Cozzi-Lepri A; Wyatt CM; Post FA; Bormann AM; Crum-Cianflone NF; Ross MJ, 2014, 'Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals', HIV Medicine, vol. 15, pp. 116 - 123, http://dx.doi.org/10.1111/hiv.12087
2014
Bavinton BR; Jin F; Prestage G; Zablotska I; Koelsch KK; Phanuphak N; Grinsztejn B; Cooper DA; Fairley C; Kelleher A; Triffitt K; Grulich AE, 2014, 'The Opposites Attract Study of viral load, HIV treatment and HIV transmission in serodiscordant homosexual male couples: Design and methods', BMC Public Health, vol. 14, http://dx.doi.org/10.1186/1471-2458-14-917
2014
Cummins NW; Neuhaus J; Sainski AM; Strausbauch MA; Wettstein PJ; Lewin SR; Plana M; Rizza SA; Temesgen Z; Touloumi G; Freiberg M; Neaton J; Badley AD, 2014, 'Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41', AIDS Research and Human Retroviruses, vol. 30, pp. 476 - 479, http://dx.doi.org/10.1089/aid.2013.0243
2014
Murray JM; Zaunders JJ; McBride KL; Xu Y; Bailey M; Suzuki K; Cooper DA; Emery S; Kelleher AD; Koelsch KK, 2014, 'HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy', Journal of Virology, vol. 88, pp. 3516 - 3526, http://dx.doi.org/10.1128/JVI.03331-13
2014
Borges AH; O'Connor JL; Phillips AN; Baker JV; Vjecha MJ; Losso MH; Klinker H; Lopardo G; Williams I; Lundgren JD, 2014, 'Factors associated with D-dimer levels in HIV-infected individuals', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0090978
2014
Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Emery S; Foulkes S; Hill A; Jessen H; Kumar S; Lee MP; Losso M; Nwizu C; Phanuphak P; Ripin D; Read T; Rooney J; Schaffer K; Shahar E; Winston A; Wolff M; Young B; Abela C; Boyd M; Carey D; Clarke A; Courtney-Vega K; Dazo C; Delfino M; Donaldson A; Espinosa N; Johannesen T; Kaew-On P; Lin E; Moricz A; Taylor J; Phanupak P; Puls RL; Pussadee K; Sutheerasak P; Tomkins L; Ubolyam S; Shah Bin Raja Azwa RI; Bissio E; Calanni L; Casiro A; Chetchotisakd P; Contarelli J; Doong N; Elliott J; Gazzard B; Kelly M; Del Carmen Luna N; Lupo S; Messina OG; Mohapi L; Moore R; Nolan D; Orrell C; Perez C; Pett S; Rockstroh J; Supparatpinyo K; Smith D; Villanueva JA; Vlahakis E; Kelleher T; Cunningham P; Merlin K; Yeung J; Shaik A; Fsadni B; Carrera A; Lograsso M; Gulick R; Crabtree-Ramiraz B; Winston E; Dunn D; Dolan M, 2014, 'Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial', The Lancet, vol. 383, pp. 1474 - 1482, http://dx.doi.org/10.1016/S0140-6736(13)62187-X
2014
Borges AH; Weitz JI; Collins G; Baker JV; Lévy Y; Davey RT; Phillips AN; Neaton JD; Lundgren JD; Deeks SG, 2014, 'Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease', AIDS, vol. 28, pp. 1791 - 1796, http://dx.doi.org/10.1097/QAD.0000000000000344
2014
Boyd MA, 2013, 'Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): A randomised, open-label, non-inferiority study', Lancet, vol. 381, pp. 2091 - 2099, http://dx.doi.org/10.1016/S0140-6736(13)61164-2
2013
Tu E; Swenson LC; Land S; Pett S; Emery S; Marks K; Kelleher AD; Kaye S; Kaiser R; Schuelter E; Harrigan R, 2013, 'Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc switch collaborative study', Journal of Clinical Microbiology, vol. 51, pp. 2063 - 2071, http://dx.doi.org/10.1128/JCM.00510-13
2013
Davey Jr R; Lynfield R; Dwyer DE; Losso MH; Cozzi-Lepri A; Wentworth D; Lane HC; Dewar RL; Pett SL; Uyeki TM; Angus BJ; Cummins NW; Lundgren JD; Neaton JD, 2013, 'The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies', PLoS ONE, vol. 8, pp. e57121, http://dx.doi.org/10.1371/journal.pone.0057121
2013
Gupta M; Miller CJ; Baker JV; Lazar J; Bogner JR; Calmy A; Soliman EZ; Neaton JD, 2013, 'Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infection', American Journal of Cardiology, vol. 111, pp. 760 - 764, http://dx.doi.org/10.1016/j.amjcard.2012.11.032
2013
Andrade BB; Hullsiek KH; Boulware DR; Rupert A; French MA; Ruxrungtham K; Montes ML; Price H; Barreiro P; Audsley J; Sher A; Lewin SR; Sereti I, 2013, 'Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses', Journal of Infectious Diseases, vol. 207, pp. 1379 - 1388, http://dx.doi.org/10.1093/infdis/jit033
2013
Schneider K; Nwizu CA; Kaplan R; Anderson JS; Wilson DP; Emery S; Cooper DA; Boyd MA, 2013, 'The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa', PLoS ONE, vol. 8, pp. e54435, http://dx.doi.org/10.1371/journal.pone.0054435
2013
Grund B; Wright EJ; Brew BJ; Price RW; Roediger MP; Bain MP; Hoy JF; Shlay JC; Vjecha MJ; Robertson KR, 2013, 'Improved neurocognitive test performance in both arms of the SMART study: Impact of practice effect', Journal of NeuroVirology, vol. 19, pp. 383 - 392, http://dx.doi.org/10.1007/s13365-013-0190-x
2013
Dawood FZ; Khan F; Roediger MP; Zhang ZM; Swaminathan S; Klinker H; Hoy J; Lundgren JD; Neaton JD; Soliman EZ, 2013, 'Electrocardiographic spatial QRS-T angle and incident cardiovascular disease in hiv-infected patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] Study)', American Journal of Cardiology, vol. 111, pp. 118 - 124, http://dx.doi.org/10.1016/j.amjcard.2012.08.054
2013
Rodger AJ; Lodwick RK; Schechter M; Deeks SG; Amin J; Gilson RJC; Paredes R; Bakowska E; Engsig FN; Phillips AN, 2013, 'Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population', AIDS, vol. 27, pp. 973 - 979, http://dx.doi.org/10.1097/QAD.0b013e32835cae9c
2013
Kent SJ; Reece JC; Petravic J; Martyushev A; Kramski M; De Rose R; Cooper DA; Kelleher AD; Emery S; Cameron PU; Lewin SR; Davenport MP, 2013, 'The search for an HIV cure: Tackling latent infection', The Lancet Infectious Diseases, vol. 13, pp. 614 - 621, http://dx.doi.org/10.1016/S1473-3099(13)70043-4
2013
Rotger M; Glass TR; Junier T; Lundgren J; Neaton JD; Poloni ES; Van 'T Wout AB; Lubomirov R; Colombo S; Martinez R; Rauch A; Günthard HF; Neuhaus J; Wentworth D; Van Manen D; Gras LA; Schuitemaker H; Albini L; Torti C; Jacobson LP; Li X; Kingsley LA; Carli F; Guaraldi G; Ford ES; Sereti I; Hadigan C; Martinez E; Arnedo M; Egaña-Gorroño L; Gatell JM; Law M; Bendall C; Petoumenos K; Rockstroh J; Wasmuth JC; Kabamba K; Delforge M; De Wit S; Berger F; Mauss S; De Paz Sierra M; Losso M; Belloso WH; Leyes M; Campins A; Mondi A; De Luca A; Bernardino I; Barriuso-Iglesias M; Torrecilla-Rodriguez A; Gonzalez-Garcia J; Arribas JR; Fanti I; Gel S; Puig J; Negredo E; Gutierrez M; Domingo P; Fischer J; Fätkenheuer G; Alonso-Villaverde C; MacKen A; Woo J; McGinty T; Mallon P; Mangili A; Skinner S; Wanke CA; Reiss P; Weber R; Bucher HC; Fellay J; Telenti A; Tarr PE, 2013, 'Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons', Clinical Infectious Diseases, vol. 57, pp. 112 - 121, http://dx.doi.org/10.1093/cid/cit196
2013
Bjerk SM; Baker J; Emery S; Neuhaus JA; Angus BJ; Gordin F; Pett SL; Stephan C; Kunisaki KM, 2013, 'Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study', PLoS ONE, vol. 8, pp. e56249, http://dx.doi.org/10.1371/journal.pone.0056249
2013
Murray JM; Zaunders JJ; Koelsch KK; Natarajan V; Badralmaa Y; McBride K; Carrera A; Cooper DA; Emery S; Kelleher AD, 2013, 'Short communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreporting', AIDS Research and Human Retroviruses, vol. 29, pp. 1621 - 1625, http://dx.doi.org/10.1089/aid.2013.0132
2013
Martin A; Moore C; Mallon PWG; Hoy J; Emery S; Belloso W; Phanuphak P; Ferret S; Cooper DA; Boyd MA, 2013, 'Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy', AIDS, vol. 27, pp. 2403 - 2411, http://dx.doi.org/10.1097/01.aids.0000432534.47217.b4
2013
Soliman EZ; Roediger MP; Duprez DA; Knobel H; Elion R; Neaton JD, 2013, 'Protease inhibitors and cardiac autonomic function in HIV-infected patients: a cross-sectional analysis from the Strategies for Management of Antiretroviral Therapy (SMART) Trial', BMJ OPEN, vol. 3, http://dx.doi.org/10.1136/bmjopen-2012-002523
2013
Byakwaga H; Petoumenos K; Ananworanich J; Zhang F; Boyd MA; Sirisanthana T; Li PCK; Lee C; Mean CV; Saphonn V; Omar SFS; Pujari S; Phanuphak P; Lim PL; Kumarasamy N; Chen YMA; Merati TP; Sungkanuparph S; Ditangco R; Oka S; Tau G; Zhou J; Law MG; Emery S, 2013, 'Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: Results from the TREAT Asia HIV Observational Database', Journal of the International Association of Providers of AIDS Care, vol. 12, pp. 270 - 277, http://dx.doi.org/10.1177/1545109712469684
2013
Martin A; Moore CL; Mallon PWG; Hoy JF; Emery S; Belloso WH; Phanuphak P; Ferret S; Cooper DA; Boyd MA; Second-Line Study Team , 2013, 'HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.', PloS one, vol. 8, http://dx.doi.org/10.1371/journal.pone.0077138
2013
Borges AH; Silverberg MJ; Wentworth D; Grulich AE; Fätkenheuer G; Mitsuyasu R; Tambussi G; Sabin CA; Neaton JD; Lundgren JD, 2013, 'Predicting risk of cancer during HIV infection: The role of inflammatory and coagulation biomarkers', AIDS, vol. 27, pp. 1433 - 1441, http://dx.doi.org/10.1097/QAD.0b013e32835f6b0c
2013
Baker JV; Brummel-Ziedins K; Neuhaus J; Duprez D; Cummins N; Dalmau D; DeHovitz J; Lehmann C; Sullivan A; Woolley I; Kuller L; Neaton JD; Tracy RP; INSIGHT SMART Study Team , 2013, 'HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation.', Journal of the American Heart Association, vol. 2, http://dx.doi.org/10.1161/JAHA.113.000264
2013
O'Connor JL; Gardner EM; Mannheimer SB; Lifson AR; Esser S; Telzak EE; Phillips AN, 2013, 'Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial', Journal of Infectious Diseases, vol. 208, pp. 40 - 49, http://dx.doi.org/10.1093/infdis/jis731
2013
Crawford KW; Ripin DHB; Levin AD; Campbell JR; Flexner C, 2012, 'Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: A consensus statement', The Lancet Infectious Diseases, vol. 12, pp. 550 - 560, http://dx.doi.org/10.1016/S1473-3099(12)70134-2
2012
Duerr A; Huang Y; Buchbinder S; Coombs RW; Sanchez J; Del Rio C; Casapia M; Santiago S; Gilbert P; Corey L; Robertson MN, 2012, 'Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)', Journal of Infectious Diseases, vol. 206, pp. 258 - 266, http://dx.doi.org/10.1093/infdis/jis342
2012
Carey DL; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray J; Boyd MA; Emery S; Cooper DA, 2012, 'A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults', JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 60, pp. 143 - 149, http://dx.doi.org/10.1097/QAI.0b013e318252f97e
2012
Ledwaba L; Tavel JA; Khabo P; Maja P; Qin J; Sangweni P; Liu X; Follmann D; Metcalf JA; Orsega S; Baseler B; Neaton JD; Lane HC, 2012, 'Pre-ART Levels of Inflammation and Coagulation Markers Are Strong Predictors of Death in a South African Cohort with Advanced HIV Disease', PLOS ONE, vol. 7, http://dx.doi.org/10.1371/journal.pone.0024243
2012
Hamlyn E; Ewings FM; Porter K; Cooper DA; Tambussi G; Schechter MT; Pedersen C; Okulicz JF; Mcclure MO; Babiker AG, 2012, 'Plasma HIV Viral Rebound following Protocol-Indicated Cessation of ART Commenced in Primary and Chronic HIV Infection', PLoS ONE, vol. 7, pp. Article numbere43754, http://dx.doi.org/10.1371/journal.pone.0043754
2012
Else L; Jackson A; Puls R; Hill A; Fahey P; Lin E; Amara A; Siccardi M; Watson V; Tjia JF; Emery S; Khoo SK; Back D; Boffito M, 2012, 'Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: Results of the ENCORE 2 study', Antimicrobial Agents and Chemotherapy, vol. 56, pp. 1427 - 1433, http://dx.doi.org/10.1128/AAC.05599-11
2012
Cordery D; Martin A; Kelleher AD; Emery S; Cooper DA, 2012, 'The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV.', AIDS, vol. 26, pp. 2337 - 2344, http://dx.doi.org/10.1097/QAD.0b013e32835ab213
2012
Baker JV; Neuhaus J; Duprez D; Freiberg M; Bernardino JI; Badley AD; Nixon DE; Lundgren JD; Tracy RP; Neaton JD, 2012, 'HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction', Journal of Acquired Immune Deficiency Syndromes, vol. 60, pp. 128 - 134, http://dx.doi.org/10.1097/QAI.0b013e318252f99f
2012
Winston A; Duncombe CJ; Li PCK; Gill JM; Kerr SJ; Puls R; Taylor-Robinson SD; Emery S; Cooper DA, 2012, 'Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy.', Neuroradiology, vol. 54, pp. 1331 - 1339, http://dx.doi.org/10.1007/s00234-012-1061-5
2012
Haskelberg H; Hoy J; Amin J; Ebeling PR; Emery S; Carr AD, 2012, 'Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine', PLoS ONE, vol. 7, pp. e38377, http://dx.doi.org/10.1371/journal.pone.0038377
2012
Duprez DA; Neuhaus J; Kuller LH; Tracy R; Belloso W; De Wit S; Drummond F; Lane HC; Ledergerber B; Lundgren J; Nixon D; Paton NI; Prineas RJ; Neaton JD, 2012, 'Inflammation, coagulation and cardiovascular disease in HIV-infected individuals', PLoS ONE, vol. 7, http://dx.doi.org/10.1371/journal.pone.0044454
2012
Murray JM; McBride K; Boesecke C; Bailey MR; Amin J; Suzuki K; Baker D; Zaunders JJ; Emery S; Cooper DA; Koelsch KK; Kelleher AD, 2012, 'Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards', AIDS, vol. 26, pp. 543 - 550, http://dx.doi.org/10.1097/QAD.0b013e328350fb3c
2012
Babiker AG; Emery S; Faetkenheuer G; Gordin FM; Grund B; Lundgren JD; Neaton JD; Pett SL; Phillips A; Touloumi G; Vjecha MJ, 2012, 'Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study', CLINICAL TRIALS, pp. 1 - 32, http://dx.doi.org/10.1177/1740774512440342
2012
Winston A; Puls R; Kerr SJ; Duncombe CJ; Li PCK; Gill JM; Taylor-Robinson SD; Emery S; Cooper DA, 2012, 'Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: A randomized, controlled study', HIV Medicine, vol. 13, pp. 245 - 251, http://dx.doi.org/10.1111/j.1468-1293.2011.00962.x
2012
Achhra AC; Amin J; Sabin C; Chu H; Dunn D; Kuller LH; Kovacs JA; Cooper DA; Emery S; Law MG, 2012, 'Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals', AIDS, vol. 26, pp. 1707 - 1717, http://dx.doi.org/10.1097/QAD.0b013e328355d659
2012
Martin A; Amin J; Emery S; Baker D; Carr AD; Cooper DA; Bloch M, 2011, 'Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or Abacavir-Lamivudine', PLoS One, vol. 6, pp. Article number e26885, http://dx.doi.org/10.1371/journal.pone.0026885
2011
Matthews G; Manzini P; Hu Z; Khabo P; Maja P; Matchaba G; Sangweni P; Metcalf K; Pool N; Orsega S; Emery S, 2011, 'Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa', AIDS, vol. 25, pp. 1727 - 1735, http://dx.doi.org/10.1097/QAD.0b013e328349bbf3
2011
Baker J; Neuhaus J; Duprez D; Kuller LH; Tracy R; Belloso WH; De Wit S; Drummond F; Lane HC; Ledergerber B; Lundgren JD; Nixon DE; Paton NI; Neaton JD, 2011, 'Changes in inflammatory and coagulation biomarkers: A randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection', JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 56, pp. 36 - 43, http://dx.doi.org/10.1097/QAI.0b013e3181f7f61a
2011
Peters L; Neuhaus J; Mocroft A; Soriano V; Rockstroh J; Dore G; Puoti M; Tedaldi E; Clotet B; Kupfer B; Lundgren JD; Klein MB, 2011, 'Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART study', Antiviral Therapy, vol. 16, pp. 667 - 675, http://dx.doi.org/10.3851/IMP1815
2011
Cordery DV; Humphries A; Amin J; Kelleher AD; Emery S; Cooper DA, 2011, 'The influence of HLA supertype on thymidine analogue induced body composition changes in STEAL', ANTIVIRAL THERAPY, vol. 16, pp. A20 - A21, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294375900025&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2011
Sandler NG; Wand H; Roque A; Law M; Nason M; Nixon DE; Pedersen C; Ruxrungtham K; Lewin S; Emery S; Neaton JD; Brenchley JM; Deeks SG; Sereti I; Douek D, 2011, 'Plasma levels of soluble CD14 independently predict mortality in HIV infection', Journal of Infectious Diseases, vol. 203, pp. 780 - 790, http://dx.doi.org/10.1093/infdis/jiq118
2011
Soliman EZ; Prineas R; Roediger M; Duprez D; Boccara F; Boesecke C; Stephan C; Hodder S; Stein JH; Lundgren JD; Neaton JD, 2011, 'Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: Results from the Strategies for Management of Antiretroviral Therapy study', Journal of Electrocardiology, vol. 44, pp. 779 - 785, http://dx.doi.org/10.1016/j.jelectrocard.2010.10.027
2011
Dlamini JN; Hu Z; Ledwaba J; Morris L; Maldarelli FM; Dewar RL; Highbarger HC; Somaroo H; Sangweni P; Follmann DA; Pau AK, 2011, 'Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa', Journal of Acquired Immune Deficiency Syndromes, vol. 58, pp. 304 - 308, http://dx.doi.org/10.1097/QAI.0b013e3182278c29
2011
Revell ; Wang ; Boyd MA; Emery S; Pozniak A; de WF; Harrigan R; Montaner JSG; Lane C; Larder B, 2011, 'The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool', AIDS, vol. 25, pp. 1855 - 1863, http://dx.doi.org/10.1097/QAD.0b013e328349a9c2
2011
Feeney ER; Chazallon C; O''brien N; Meiffredy V; Goodall R; Aboulker J; Cooper DA; Yeni PG; Mallon PW, 2011, 'Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial)', HIV Medicine, vol. 12, pp. 602 - 609, http://dx.doi.org/10.1111/j.1468-1293.2011.00934.x
2011
Wand HC; Carey DL; Calmy A; Law MG; Cooper DA; Emery S; Carr AD, 2011, 'Prospective evidence that HIV lipoatrophy and visceral adiposity are partially independent processes', Open Access Journal of Clinical Trials, vol. 3, pp. 1 - 7, http://dx.doi.org/10.2147/OAJCT.S14359
2011
Haskelberg H; Hoy J; Amin J; Ebeling PR; Emery S; Carr A, 2011, 'Lower fat mass and lower bone formation predict greater bone loss with tenofovir in HIV-infected adults', ANTIVIRAL THERAPY, vol. 16, pp. A6 - A7, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294375900007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2011
Haskelberg H; Carr AD; Emery S, 2011, 'Bone turnover markers in HIV disease', AIDS Reviews, vol. 13, pp. 240 - 250, http://www.aidsreviews.com/files/2011_13_4_240-250.pdf
2011
Duprez DA; Neuhaus J; Tracy R; Kuller LH; Deeks SG; Orkin C; Stoehr A; Woolley IJ; Neaton JD, 2011, 'N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients', AIDS, vol. 25, pp. 651 - 657, http://dx.doi.org/10.1097/QAD.0b013e32834404a1
2011
Pett SL; Carey C; Lin E; Wentworth D; Lazovski J; Miro J; Gordin F; Angus B; Rodriguez-Barradas M; Rubio R; Tambussi G; Cooper DA; Emery S, 2011, 'Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)', HIV Medicine, vol. 12, pp. 219 - 227, http://dx.doi.org/10.1111/j.1468-1293.2010.00875.x
2011
Jackson A; Hill A; Puls R; Else L; Amin J; Back D; Lin E; Khoo S; Emery S; Morley R; Gazzard B; Boffito M, 2011, 'Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers', Journal of Antimicrobial Chemotherapy, vol. 66, pp. 635 - 640, http://dx.doi.org/10.1093/jac/dkq468
2011
Smith W; Grady C; Krohmal B; Lazovski J; Wendler D, 2011, 'Empirical evaluation of the need for 'on-going consent' in clinical research', AIDS, vol. 25, pp. 107 - 114, http://dx.doi.org/10.1097/QAD.0b013e328340fec7
2011
Mocroft A; Lifson AR; Touloumi G; Neuhaus J; Fox Z; Palfreeman A; Vjecha MJ; Hodder S; De Wit S; Lundgren JD; Phillips AN, 2011, 'Haemoglobin and anaemia in the SMART study', Antiviral Therapy, vol. 16, pp. 329 - 337, http://dx.doi.org/10.3851/IMP1746
2011
Soliman EZ; Lundgren JD; Roediger MP; Duprez DA; Temesgen Z; Bickel M; Shlay JC; Somboonwit C; Reiss P; Stein JH; Neaton JD, 2011, 'Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations', AIDS, vol. 25, pp. 367 - 377, http://dx.doi.org/10.1097/QAD.0b013e328341dcc0
2011
Cozzi-Lepri A; French MA; Baxter J; Okhuysen P; Plana M; Neuhaus J; Landay A, 2011, 'Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trial', AIDS, vol. 25, pp. 1207 - 1217, http://dx.doi.org/10.1097/QAD.0b013e3283471f10
2011
Byakwaga H; Purcell DJ; French MA; Amin J; Lewin S; Haskelberg H; Kelleher AD; Garsia RJ; Boyd MA; Cooper DA; Emery S, 2011, 'Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4 + T-cell response: A randomized controlled trial', Journal of Infectious Diseases, vol. 204, pp. 1532 - 1540, http://dx.doi.org/10.1093/infdis/jir559
2011
Baker J; Neuhaus JA; Duprez D; Cooper DA; Hoy J; Kuller LH; Lampe FC; Liappis A; Friis-Moller N; Otvos J; Paton NI; Tracy R; Neaton JD, 2011, 'Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy', AIDS, vol. 25, pp. 2133 - 2142, http://dx.doi.org/10.1097/QAD.0b013e32834be088
2011
Dwyer DE; Davey R; Losso MH; Lynfield R; Cozzi-Lepri A; Gey D; Herman-Lamin K; Hoppe A; Lane ; Lundgren JD; Neaton JD; Pett SL; Standridge B; Uyeki M; Wentworth D, 2011, 'Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site netwok approach: The INSIGHT FLU 002 and FLU 003 studies', Vaccine, vol. 29, pp. B56 - B62, http://dx.doi.org/10.1016/j.vaccine.2011.04.105
2011
Fitzgerald DW; Janes H; Robertson M; Coombs R; Frank I; Gilbert P; Loufty M; Mehrotra D; Duerr A, 2011, 'An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: Results from a randomized placebo-controlled trial (The step study)', Journal of Infectious Diseases, vol. 203, pp. 765 - 772, http://dx.doi.org/10.1093/infdis/jiq114
2011
Koelsch KK; Boesecke C; Mcbride K; Gelgor L; Fahey P; Natarajan V; Baker D; Bloch M; Murray JM; Zaunders J; Emery S; Cooper DA; Kelleher AD, 2011, 'Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir', AIDS, vol. 25, pp. 2069 - 2078, http://dx.doi.org/10.1097/QAD.0b013e32834b9658
2011
Boulware DR; Hullsiek KH; Puronen CE; Rupert A; Baker JV; French MA; Bohjanen PR; Novak RM; Neaton JD; Sereti I, 2011, 'Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death', Journal of Infectious Diseases, vol. 203, pp. 1637 - 1646, http://dx.doi.org/10.1093/infdis/jir134
2011
Amin J; De lazzari E; Emery S; Martin A; Martinez E; Carr AD; Gatell J; Cooper DA, 2010, 'Simplification with fixed-dose tenofovir-emtricitabine or abacavir-lamivudine in treatment experienced, virologically suppressed adults with HIV infection: combined analysis of two randomised, non-inferiority trials Bicombo and Steal.', Journal of AIDS & Clinical Research, vol. 1, pp. 1001 - 1013, http://dx.doi.org/10.4172/2155-6113.1000103
2010
Neuhaus J; Angus B; Kowalska JD; La Rosa A; Sampson J; Wentworth D; Mocroft A, 2010, 'Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV', AIDS, vol. 24, pp. 697 - 706, http://dx.doi.org/10.1097/QAD.0b013e3283365356
2010
Winston A; Duncombe C; Li P; Gill JM; Kerr SJ; Puls R; Petoumenos K; Taylor-Robinson SD; Emery S; Cooper DA, 2010, 'Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study', Clinical Infectious Diseases, vol. 50, pp. 920 - 929, http://dx.doi.org/10.1086/650743
2010
Martinez E; Visnegarwala F; Grund B; Thomas A; Gibert C; Shlay J; Drummond F; Pearce D; Edwards S; Reiss P; El-Sadr W; Carr AD, 2010, 'The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters', AIDS, vol. 24, pp. 353 - 363, http://dx.doi.org/10.1097/QAD.0b013e3283333666
2010
Tavel JA; Babiker A; Carey C; Fisher M; Fox L; Gey D; Lopardo GD; Lopez JC; Markowitz N; Munroe D; Paton N; Ruxrungtham K; Standridge B; Wentworth D; Wyman N; Aagaard B; Borup L; Grarup J; Jansson PO; Jensen K; Lundgren J; Mollerup D; Reilev S; Braimah N; Darbyshire J; Horton J; King E; Smith N; Van Hooff F; Cooper DA; Courtney-Rodgers D; Emery S; Finley E; Gordin F; Sánchez A; Thomas D; Bebchuk J; Bollenbeck P; Denning E; DuChene AG; Fosdick L; Harrison M; Krum E; Larson G; Neaton JD; Nelson R; Quan K; Quan SFL; Schultz T; Thompson G; Collins S; Haerry DH; Meulbroek M; Peavy D; Rappoport C; Schwarze S; Valdez M; Watson J; Belloso WH; Davey R; Duprez D; Gatell JM; Hoy J; Lifson A; Pederson C; Perez G; Price R; Prineas R; Rhame F; Sampson JH; Worley J; Modlin JF; Beral V; Chaisson RE; Fleming TR; Hill C; Kim KM; Murray BE; Pick B; Seligmann M; Weller I; Luzar MA; Martinez A; Costas V; Eckstrand J; Brown S; Lupo SH; Losso MH; Anderson J; Chuah J; Kelly M; Orth D; Wolff MJ; Rusconi S; Tambussi G; Horban A; Antunes F; Mansinho K; Da Conceicao Vera JAV; Himmich H, 2010, 'Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: The STALWART study', PLoS ONE, vol. 5, http://dx.doi.org/10.1371/journal.pone.0009334
2010
Dore GJ; Soriano V; Rockstroh J; Kupfer B; Tedaldi E; Peters L; Neuhaus J; Puoti M; Klein M; Mocroft A; Clotet B; Lundgren JD, 2010, 'Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption', AIDS, vol. 24, pp. 857 - 865, http://dx.doi.org/10.1097/QAD.0b013e328334bddb
2010
Sellier P; Lafuente-Lafuente C; Bergmann J-F, 2010, 'Interleukin-2 Therapy in Patients with HIV Infection', NEW ENGLAND JOURNAL OF MEDICINE, vol. 362, pp. 270 - 271, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000273738400020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2010
Hassim S; Shaw PA; Sangweni P; Malan L; Ntshani E; Mathibedi MJ; Stubbs N; Metcalf JA; Eckes R; Masur H; Komati S, 2010, 'Detection of a substantial rate of multidrug-resistant tuberculosis in an HIV-infected population in South Africa by active monitoring of sputum samples', Clinical Infectious Diseases, vol. 50, pp. 1053 - 1059, http://dx.doi.org/10.1086/651119
2010
Pett SL; Zaunders J; Bailey M; Murray JM; Macrae K; Emery S; Cooper DA; Kelleher AD, 2010, 'A novel Chemokine-Receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection', AIDS Research and Human Retroviruses, vol. 26, pp. 653 - 661, http://dx.doi.org/10.1089/aid.2009.0278
2010
Achhra A; Amin J; Law MG; Emery S; Gerstoft J; Gordin F; Vjecha M; Neaton JD; Cooper DA, 2010, 'Immunodeficiency and the risk of serious clinical endpoints in a well-studied cohort of treated HIV-infected patients.', AIDS, vol. 24, pp. 1877 - 1886, http://dx.doi.org/10.1097/QAD.0b013e32833b1b26
2010
Pett SL; Emery S; Kelleher AD; Cooper DA, 2010, 'Antiretroviral agents: Focus on Maraviroc for the Treatment of HIV-1-Infected Adults', Clinical Medicine Insights: Therapeutics, vol. 2, pp. CMT.S5420 - CMT.S5420, http://dx.doi.org/10.4137/cmt.s5420
2010
French MA; Tanaskovic S; Law MG; Lim A; Fernandez S; Ward LD; Kelleher AD; Emery S, 2010, 'Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a 'high-affinity' FcγRIIa genotype', AIDS, vol. 24, pp. 1983 - 1990, http://dx.doi.org/10.1097/QAD.0b013e32833c1ce0
2010
Pett SL; Kelleher AD; Emery S, 2010, 'Role of interleukin-2 inpatients with HIV infection', Drugs, vol. 70, pp. 1115 - 1130, http://dx.doi.org/10.2165/10898620-000000000-00000
2010
Carey DL; Amin J; Boyd MA; Petoumenos K; Emery S, 2010, 'Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomised controlled trials', Journal of Antimicrobial Chemotherapy, vol. 65, pp. 1878 - 1888, http://dx.doi.org/10.1093/jac/dkq231
2010
Puls R; Srasuebkul P; Petoumenos K; Boesecke C; Duncombe CJ; Belloso WH; Molina J; Li L; Avihingsanon A; Gazzard B; Cooper DA; Emery S, 2010, 'Efavirenz versus boosted atazanavir or zidovudine and abacavir in antirectroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study', Clinical Infectious Diseases, vol. Oct 1; 51, pp. 855 - 864, http://dx.doi.org/10.1086/656363
2010
Neaton JD; Neuhaus J; Emery S, 2010, 'Soluble biomarkers and morbidity among people infected with HIV: summary of published reports from 1997 to 2010', Current opinion in HIV & AIDS, vol. 5, pp. 480 - 490, http://dx.doi.org/10.1097/COH.0b013e32833ed75d
2010
Hemachandra A; Puls R; Sirivichayakul S; Kerr SJ; Thantiworasit P; Ubolyam S; Cooper DA; Emery S; Phanuphak P; Kelleher AD; Ruxrungtham K, 2010, 'An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection', Human Vaccines, vol. 6, pp. 835 - 840, http://dx.doi.org/10.4161/hv.6.10.12635
2010
Pett SL; Emery S; Kelleher AD; Cooper DA, 2010, 'Antiretroviral agents: Focus on maraviroc for the treatment of HIV-1-infected adults', Clinical Medicine Insights: Therapeutics, vol. 2, pp. 697 - 713, http://www.la-press.com/
2010
Ratsela A; Polis M; Dhlomo S; Emery S; Grandits G; Khabo P; Khanyile T; Komati S; Neaton JD; Naidoo LC; Magongoa D; Qolohle D, 2010, 'A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count', Journal of Infectious Diseases, vol. 202, pp. 1529 - 1537, http://dx.doi.org/10.1086/656718
2010
French MA; Tanaskovic S; Law MG; Lim A; Fernandez S; Ward LD; Kelleher AD; Emery S, 2010, 'Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a 'high-affinity' FcγRIIa genotype', AIDS, vol. 24, pp. 1938 - 1990
2010
Martin A; Amin J; Cooper DA; Carr AD; Kelleher AD; Bloch M; Baker D; Woolley I; Emery S, 2010, 'Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial', AIDS, vol. 24, pp. 2657 - 2663, http://dx.doi.org/10.1097/QAD.0b013e32833f147f
2010
Lampe FC; Duprez DA; Kuller LH; Tracy R; Otvos J; Stroes E; Cooper DA; Hoy J; Paton NI; Friis-Moller N; Neuhaus J; Liappis AP; Phillips AN, 2010, 'Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy', JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 54, pp. 275 - 284, http://dx.doi.org/10.1097/QAI.0b013e3181d32158
2010
Lifson A; Belloso W; Davey R; Duprez D; Gatell J; Hoy J; Krum E; Nelson R; Pedersen C; Perez G; Price R; Prineas R; Rhame F; Sampson J; Worley J, 2010, 'Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials', HIV Clinical Trials, vol. 11, pp. 205 - 219, http://dx.doi.org/10.1310/hct1104-205
2010
Wright EJ; Grund B; Robertson K; Brew BJ; Roediger M; Bain MP; Drummond F; Vjecha MJ; Hoy J; Miller C; Penalva de Oliveira AC; Pumpradit W; Shlay JC; El-Sadr W; Price RW, 2010, 'Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons', Neurology, vol. 75, pp. 864 - 873, http://dx.doi.org/10.1212/WNL.0b013e3181f11bd8
2010
Neuhaus J; Jacobs DR; Baker JV; Calmy A; Duprez D; La Rosa A; Kuller LH; Pett SL; Ristola M; Ross M; Shlipak MG; Tracy R; Neaton JD, 2010, 'Markers of inflammation, coagulation and renal function are elevated in adults with HIV infection', Journal of Infectious Diseases, vol. 201, pp. 1788 - 1795, http://dx.doi.org/10.1086/652749
2010
Lifson AR; Neuhaus J; Ramon Arribas J; van den Berg-Wolf M; Labriola AM; Read TRH, 2010, 'Smoking-Related Health Risks Among Persons With HIV in the Strategies for Management of Antiretroviral Therapy Clinical Trial', AMERICAN JOURNAL OF PUBLIC HEALTH, vol. 100, pp. 1896 - 1903, http://dx.doi.org/10.2105/AJPH.2009.188664
2010
Grund B; Neuhaus J; Phillips A, 2009, 'Relative risk of death in the SMART study', LANCET INFECTIOUS DISEASES, vol. 9, pp. 724 - 725, http://dx.doi.org/10.1016/S1473-3099(09)70302-0
2009
Samaras K; Wand HC; Law MG; Emery S; Cooper DA; Carr AD, 2009, 'Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism', Current HIV Research, vol. 7, pp. 454 - 461, http://dx.doi.org/10.2174/157016209788680589
2009
Hemachandra A; Puls RL; Kerr SJ; Saengthong N; Pussadee K; Emery S; Phanuphak P; Ruxrungtham K, 2009, 'P15-01. Willingness to participate in actual preventive HIV vaccine phase I/IIa trial in Bangkok, Thailand', Retrovirology, vol. 6, http://dx.doi.org/10.1186/1742-4690-6-S3-P202
2009
Rodger A; Fox Z; Lundgren JD; Kuller LH; Boesecke C; Gey D; Skoutelis ; Goetz M; Phillips AN, 2009, 'Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection', Journal of Infectious Diseases, vol. 200, pp. 973 - 983, http://dx.doi.org/10.1086/605447
2009
Byakwaga H; Boesecke C; Emery S, 2009, 'Inflammation and gut permeability', Journal of Hiv Therapy, vol. 14, pp. 57 - 60, http://www.thefreelibrary.com/Inflammation+and+gut+permeability.-a0213312726
2009
Martin A; Bloch MT; Amin J; Baker DL; Cooper DA; Emery S; Carr AD, 2009, 'Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial', Clinical Infectious Diseases, vol. 49, pp. 1591 - 1601, http://dx.doi.org/10.1086/644769
2009
Mocroft A; Wyatt C; Szczech L; Neuhaus J; El-Sadr W; Tracy R; Kuller L; Shlipak M; Angus B; Klinker H; Ross M, 2009, 'Interruption of antiretroviral therapy is associated with increased plasma cystatin C', AIDS, vol. 23, pp. 71 - 82, http://dx.doi.org/10.1097/QAD.0b013e32831cc129
2009
Lazovski J; Losso M; Krohmal B; Emanuel EJ; Grady C; Wendler D, 2009, 'BENEFITS AND BURDENS OF PARTICIPATION IN A LONGITUDINAL CLINICAL TRIAL', JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS, vol. 4, pp. 89 - 97, http://dx.doi.org/10.1525/jer.2009.4.3.89
2009
Pett SL, 2009, 'Immunotherapies in HIV-1 infection', Current opinion in HIV & AIDS, vol. 4, pp. 188 - 193, http://dx.doi.org/10.1097/COH.0b013e328329d090
2009
Duprez D; Kuller LH; Tracy R; Otvos J; Cooper DA; Hoy JF; Neuhaus J; Paton N; Friis-Moller N; Lampe F; Liappis A; Neaton JD, 2009, 'Lipoprotein particle subclasses, cardiovascular disease and HIV infection', Atherosclerosis, vol. 207, pp. 524 - 529, http://dx.doi.org/10.1016/j.atherosclerosis.2009.05.001
2009
Byakwaga H; Murray JM; Petoumenos K; Kelleher AD; Law MG; Boyd MA; Emery S; Mallon PW; Cooper DA, 2009, 'Evolution of CD4+T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression', AIDS Research and Human Retroviruses, vol. 25, pp. 569 - 576, http://dx.doi.org/10.1089/aid.2008.0149
2009
Boyd MA; Emery S; Cooper DA, 2009, 'Antiretroviral roll-out: the problem of second-line therapy', Lancet, vol. 374, pp. 185 - 186, http://dx.doi.org/10.1016/S0140-6736(09)61313-1
2009
Zaunders J; Munier ML; Seddiki N; Pett SL; Ip S; Bailey M; Xu Y; Brown KJ; Dyer W; Kim MS; De Rose R; Kent SJ; Jiang L; Breit SN; Emery S; Cunningham AL; Cooper DA; Kelleher AD, 2009, 'High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40)', Journal of Immunology, vol. 183, pp. 2827 - 2836, http://dx.doi.org/10.4049/jimmunol.0803548
2009
Phillips A; Emery S, 2009, 'Editorial introductions', Current Opinion in HIV and AIDS, vol. 4, http://dx.doi.org/10.1097/COH.0b013e32832aad28
2009
Read TRH; Carey DL; Mallon PW; Mijch A; Goodall R; Hudson F; Wand HC; Emery S, 2009, 'Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial', AIDS, vol. 23, pp. 2222 - 2223, http://dx.doi.org/10.1097/QAD.0b013e32832e95f8
2009
Phillips A; Emery S, 2009, 'Predicting the potential benefits of early initiation of ART: Time to do a trial to find out', Current opinion in HIV & AIDS, vol. 4, pp. 165 - 166, http://dx.doi.org/10.1097/COH.0b013e328329ec32
2009
Pett SL; Mccarthy M; Cooper DA; MacRae K; Tendolkar A; Norris R; Strizki J; Williams KM; Emery S, 2009, 'A Phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients', Antiviral Therapy, vol. 14, pp. 111 - 115
2009
Grulich AE, 2009, 'Cancer: The effects of HIV and antiretroviral therapy, and implications for early antiretroviral therapy initiation', Current opinion in HIV & AIDS, vol. 4, pp. 183 - 187, http://dx.doi.org/10.1097/COH.0b013e328329c5b2
2009
Carey DL; Baker D; Petoumenos K; Chuah J; Rogers G; Watson J; Cooper DA; Emery S; Carr AD, 2009, 'Poly-L-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up', HIV Medicine, vol. 10, pp. 163 - 172, http://dx.doi.org/10.1111/j.1468-1293.2008.00667.x
2009
Emery S; Winston A, 2009, 'Raltegravir: a new choice in HIV and new chances for research', Lancet, vol. 374, pp. 764 - 766, http://dx.doi.org/10.1016/S0140-6736(09)61392-1
2009
Byakwaga H; Zhou J; Petoumenos K; Law MG; Boyd MA; Emery S; Cooper DA; Mallon PW, 2009, 'Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy', HIV Medicine, vol. 10, pp. 143 - 151, http://dx.doi.org/10.1111/j.1468-1293.2008.00663.x
2009
Wang D; Larder B; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; D'Arminio Monforte A; Torti C; Zazzi M; Lane C, 2009, 'A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy', Artificial Intelligence in Medicine, vol. 47, pp. 63 - 74, http://dx.doi.org/10.1016/j.artmed.2009.05.002
2009
Abrams A; Levy Y; Losso MH; Babiker AG; Collins G; Cooper DA; Darbyshire JH; Emery S; Fox L; Gordin F; Lane HC; Lundgren JD; Mitsuyasu R; Neaton J; Phillips AN; Routy J; Tambussi G; Wentworth D, 2009, 'Interleukin-2 therapy in patients with HIV infection.', New England Journal of Medicine, vol. 361, pp. 1548 - 1559, http://dx.doi.org/10.1056/NEJMoa0903175
2009
Grund B; Peng G; Gibert C; Hoy JF; Isaksson R; Shlay J; Martinez E; Reiss P; Visnegarwala F; Carr AD, 2009, 'Continuous antiretroviral therapy decreases bone mineral density', AIDS, vol. 23, pp. 1519 - 1529, http://dx.doi.org/10.1097/QAD.0b013e32832c1792
2009
Martin A; Emery S, 2009, 'Metabolic disorders and cardiovascular consequences of HIV infection and antiretroviral therapy', Expert Review of Clinical Pharmacology, vol. 2, pp. 381 - 390, http://dx.doi.org/10.1586/ecp.09.11
2009
Winters B; Montaner JS; Harrigan PR; Gazzard B; Pozniak A; Miller MD; Emery S; van Leth F; Robinson P; Baxter J; Perez-Elias M; Castor D; Hammer SM; Rinehart A; Vermeiren H; Van Craenenbroeck E; Bacheler L, 2008, 'Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data', JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 48, pp. 26 - 34, http://dx.doi.org/10.1097/QAI.0b013e31816d9bf4
2008
Calmy A; Carey DL; Mallon PW; Wand HC; Law MG; Cooper DA; Carr AD, 2008, 'Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy', HIV Medicine, vol. 9, pp. 101 - 110, http://dx.doi.org/10.1111/j.1468-1293.2007.00527.x
2008
El-Sadr W; Grund B; Neuhaus J; Babiker AG; Cohen C; Darbyshire JH; Emery S; Phillips A; Lundgren JD; Neaton JD, 2008, 'Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy - a randomized trial', Annals of Internal Medicine, vol. 149, pp. 289 - W62, http://dx.doi.org/10.7326/0003-4819-149-5-200809020-00003
2008
Lifson A; Belloso WH; Carey C; Davey R; Duprez D; El-Sadr W; Gatell J; Gey D; Hoy JF; Krum E; Nelson R; Nixon D; Paton N; Pedersen C; Perez G; Price RA; Prineas R; Rhame F; Sampson J; Worley J, 2008, 'Determination of the underlying cause of death in three multicenter international HIV clinical trials', HIV Clinical Trials, vol. 9, pp. 177 - 185, http://dx.doi.org/10.1310/hct0903-177
2008
Cooper DA; Emery S; Cordery D, 2008, 'Disease progression and fatal outcomes in HIV-infected patients during interruption of antiretroviral treatment', Journal of Infectious Diseases, vol. 197, pp. 775 - 775, http://dx.doi.org/10.1086/527399
2008
Kuller LH; Tracy R; Belloso WH; De Wit S; Drummond F; Lane HC; Ledergerber B; Lundgren JD; Neuhaus J; Nixon D; Paton N; Neaton JD, 2008, 'Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection', PLOS Medicine, vol. 5, pp. 1496 - 1508, http://dx.doi.org/10.1371/journal.pmed.0050203
2008
Carey DL; Liew S; Emery S, 2008, 'Restorative interventions for HIV facial lipoatrophy', AIDS Reviews, vol. 10, pp. 116 - 124
2008
Tedaldi E; Peters L; Neuhaus J; Puoti M; Rockstroh J; Klein M; Dore GJ; Mocroft A; Soriano V; Clotet B; Lundgren JD, 2008, 'Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study', Clinical Infectious Diseases, vol. 47, pp. 1468 - 1475, http://dx.doi.org/10.1086/593102
2008
Fox Z; Phillips AN; Cohen C; Neuhaus J; Baxter J; Emery S; Hirschel B; Hullsiek K; Stephan C; Lundgren JD, 2008, 'Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen', AIDS, vol. 22, pp. 2279 - 2289, http://dx.doi.org/10.1097/QAD.0b013e328311d16f
2008
Mallon PW; Sedwell R; Rogers GJ; Nolan D; Unemori P; Hoy JF; Samaras K; Kelleher AD; Emery S; Cooper DA; Carr AD, 2008, 'Effect of Rosiglitazone on Peroxisome Proliferator-Activated Receptor gamma Gene Expression in Human Adipose Tissue Is Limited by Antiretroviral Drug-Induced Mitochondrial Dysfunction', Journal of Infectious Diseases, vol. 198, pp. 1794 - 1803, http://dx.doi.org/10.1086/593179
2008
Lundgren JD; Neuhaus J; Babiker AG; Cooper DA; Duprez D; El-Sadr W; Emery S; Gordin F; Kowalska J; Prineas R; Reiss P; Sabin C; Tracy R; Weber R; Grund B; Phillips AN; Neaton JD, 2008, 'Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.', AIDS, vol. 22, pp. F17 - F24, http://dx.doi.org/10.1097/QAD.0b013e32830fe35e
2008
Emery S; Neuhaus J; Phillips A; Babiker AG; Cohen C; Gatell J; Girard P; Grund B; Law MG; Losso MH; Palfreeman A; Wood R, 2008, 'Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study', Journal of Infectious Diseases, vol. 197, pp. 1133 - 1144, http://dx.doi.org/10.1086/586713
2008
Lundgren JD; Babiker AG; El-Sadr W; Emery S; Grund B; Neaton JD; Neuhaus J; Phillips A, 2008, 'Inferior clinical outcome of the CD4(+) cell count guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4(+) cell counts and HIV RNA levels during follow-up', Journal of Infectious Diseases, vol. 197, pp. 1145 - 1155, http://dx.doi.org/10.1086/529523
2008
Burman W; Grund B; Neuhaus J; Douglas J; Friedland G; Telzak E; Colebunders R; Paton N; Fisher M; Rietmeijer C, 2008, 'Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: Results of a randomized controlled trial', JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, vol. 49, pp. 142 - 150, http://dx.doi.org/10.1097/QAI.0b013e318183a9ad
2008
Phillips AN; Carr AD; Neuhaus J; Visnegarwala F; Prineas R; Burman W; Williams IR; Drummond F; Duprez D; Belloso WH; Goebel F; Grund B; Hatzakis A; Vera J; Lundgren JD, 2008, 'Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial', Antiviral Therapy, vol. 13, pp. 177 - 187
2008
Mangclaviraj S; Kerr SJ; Chaithongwongwatthana S; Ananworanich J; Hirschel B; Emery S; Cooper DA; Chotnopparatpattara P; Ruxrungtham K; Phanuphak P, 2008, 'Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited setting', International Journal of STD and AIDS, vol. 19, pp. 529 - 532, http://dx.doi.org/10.1258/ijsa.2007.007222
2008
McElrath MJ; De Rosa SC; Moodie Z; Dubey S; Kierstead L; Janes H; Defawe OD; Carter DK; Hural J; Akondy R; Buchbinder SP; Robertson MN; Mehrotra DV; Self SG; Corey L; Shiver JW; Casimiro DR, 2008, 'HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis', The Lancet, vol. 372, pp. 1894 - 1905, http://dx.doi.org/10.1016/S0140-6736(08)61592-5
2008
Gordin FM; Roediger MP; Girard P-M; Lundgren JD; Miro JM; Palfreeman A; Rodriguez-Barradas MC; Wolff MJ; Easterbrook PJ; Clezy K; Slater LN, 2008, 'Pneumonia in HIV-infected persons - Increased risk with cigarette smoking and treatment interruption', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 178, pp. 630 - 636, http://dx.doi.org/10.1164/rccm.200804-617OC
2008
Wand HC; Calmy A; Carey DL; Samaras K; Carr AD; Law MG; Cooper DA; Emery S, 2007, 'Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV-infected adults', AIDS, vol. 21, pp. 2445 - 2453, http://dx.doi.org/10.1097/QAD.0b013e3282efad32
2007
Ellis KJ; Grund B; Visnegarwala F; Thackeray L; Miller CG; Chesson CE; El-Sadr W; Carr A, 2007, 'Visceral and subcutaneous adiposity measurements in adults: Influence of measurement site', Obesity, vol. 15, pp. 1441 - 1447, http://dx.doi.org/10.1038/oby.2007.172
2007
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A, 2007, 'Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia (vol 30, pg 113, 2007)', DIABETES CARE, vol. 30, pp. 455 - 455, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000244024100062&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2007
Bucciardini R; Fragola V; Massella M; Polizzi C; Mirra M; Goodall RL; Carey DL; Hudson FE; Zajdenverg R; Floridia M, 2007, 'Health-related quality of life outcomes in HIV-Infected patients starting different combination regimens in a randomized multinational trial: The INITIO-QoL substudy', AIDS Research and Human Retroviruses, vol. 23, pp. 1215 - 1222, http://dx.doi.org/10.1089/aid.2007.0067
2007
Larder BA; Wang D; Revell A; Montaner JS; Harrigan R; De Wolf F; Lange JM; Wegner S; Ruiz L; Perez-Elias M; Emery S; Gatell J; d Arminio Monforte A; Torti C; Zazzi M; Lane C, 2007, 'The development of artificial neural networks to predict virological response to combination HIV therapy', Antiviral Therapy, vol. 12, pp. 15 - 24
2007
Carey DL; Baker D; Rogers G; Petoumenos K; Chuah J; Easey N; Mahon K; Cooper DA; Emery S; Carr AD, 2007, 'A randomized, multicenter, open-label study of poly-l-lactic acid for HIV-1 facial lipoatrophy', JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 46, pp. 581 - 589, http://dx.doi.org/10.1097/QAI.0b013e318158bec9
2007
Samaras K; Wand HC; Law MG; Emery S; Cooper DA; Carr AD, 2007, 'Prevalence of Metabolic Syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria', Diabetes Care, vol. 30, pp. 113 - 119, http://dx.doi.org/10.2337/dc06-1075
2007
Silverberg MJ; Neuhaus J; Bower M; Gey D; Hatzakis A; Henry K; Hidalgo J; Lourtau L; Neaton JD; Tambussi G; Abrams DI, 2007, 'Risk of cancers during interrupted antiretroviral therapy in the SMART study', AIDS, vol. 21, pp. 1957 - 1963, http://dx.doi.org/10.1097/QAD.0b013e3282ed6338
2007
Fox Z; Antunes F; Davey R; Gazzard B; Klimas N; Labriola A; Losso M; Neaton JD; Phillips A; Ruxrungtham K; Staszewski S; Weiss L; Lundgren DJ; Aguilar L; Angel EB; Aquilia S; Belloso W; Benetucci J; Bittar V; Cahn P; Casiro A; Contarelli J; Corral J; Daciuk L; David D; Ferrari I; Fridman D; Galache V; Guaragna G; Ivalo S; Laplume H; Lanusse I; Lasala MB; Lattes R; Lasovsky J; Lopardo G; Lourtau L; Lupo S; Maranzana A; Marson C; Massera L; Sanchez MDL; Somenzini C; Tocci M; Algar S; Anderson J; Baker D; Blavius K; Bloch M; Boyle M; Bradford D; Britton P; Carrall L; Carr A; Chuah J; Curry M; D'Arcy-Evans C; Dobson P; Doong N; Egan C; Ferguson W; Finlayson R; French M; Frater A; Gold J; Habel P; Haig K; Holland R; Hyland N; Hoy J; Hudson J; James R; Leung J; Lowe K; MacRae K; McMurchie M; Medland N; Miller S; Murray J; Newman R; David O; Patching J; Primrose R; Ree H; Richardson R; Rogers G; Roney J; Roth N; Sarangapany J; Shaw D; Silberberg C; Skett A; Vale R; Villella C; Walker A; Watson A; Wendt N; Wood H, 2007, 'Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2', HIV Medicine, vol. 8, pp. 112 - 123, http://dx.doi.org/10.1111/j.1468-1293.2007.00440.x
2007
Byakwaga H; Zhou J; Law MG; Emery S; Mallon PW; Cooper DA, 2007, 'Effect of nucleoside reverse transcriptase inhibitors (NRTIs) on CD4 recovery for individuals on long-term, fully suppressive antiretroviral therapy (ART)', Antiviral Therapy, vol. 12, pp. L61 - L62, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000249773400113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2007
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A, 2007, 'Erratum: Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia (Diabetes Care (2007) 30, (113-119))', Diabetes Care, vol. 30, pp. 455, http://dx.doi.org/10.2337/dc07-er02
2007
Dyer W; Pett SL; Sullivan JS; Emery S; Cooper DA; Kelleher AD; Lloyd AR; Lewin S, 2007, 'Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples', Clinical and Vaccine Immunology, vol. 14, pp. 52 - 59, http://dx.doi.org/10.1128/CVI.00214-06
2007
Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law MG; Cooper DA; Emery S, 2007, 'The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation', Clinical Infectious Diseases, vol. 44, pp. 1475 - 1483, http://dx.doi.org/10.1086/517507
2007
Motumi N; Emery S; Lane C, 2007, 'Project phidisa: development of clinical research capacity within the South African National Defence Force', Current opinion in HIV & AIDS, vol. 2, pp. 69 - 76, http://dx.doi.org/10.1097/COH.0b013e328011e9c0
2007
Emery S; Kelleher AD; Workman C; Puls R; Bloch MT; Baker D; Hoy JF; Ip S; Nalliah K; Ward L; Law MG; Cooper DA, 2007, 'Influence of IFN gamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy', Human Vaccines, vol. 3, pp. 260 - 267, http://dx.doi.org/10.4161/hv.4627
2007
Murray JM; Emery S; Kelleher AD; Law MG; Chen J; Hazuda DJ; Nguyen BT; Teppler H; Cooper DA, 2007, 'Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase', AIDS, vol. 21, pp. 2315 - 2321, http://dx.doi.org/10.1097/QAD.0b013e3282f12377
2007
Youle M; Emery S; Fisher M; Nelson M; Fosdick L; Janossy G; Loveday C; Sullivan AM; Herzmann C; Wand HC; Davey Jr R; Johnson MA; Tavel JA; Lane HC, 2006, 'A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: The UK-Vanguard study.', PLoS Clinical Trials, vol. 1, pp. e3 - e3, http://dx.doi.org/10.1371/journal.pctr.0010003
2006
Pett SL; Wand HC; Law MG; Arduino R; Lopez JC; Knysz B; Pereira L; Pollack S; Reiss P; Tambussi G, 2006, 'Evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants', HIV Clinical Trials, vol. 7, pp. 70 - 85, http://dx.doi.org/10.1310/4733-ACQF-F3P4-2QAC
2006
Yeni PG; Cooper DA; Aboulker J; Babiker AG; Carey DL; Darbyshire JH; Floridia M; Girard P; Goodall R; Hooker M; Mijch AM; Meiffredy V; Salzberger B, 2006, 'Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.', Lancet, vol. 368, pp. 287 - 298, http://dx.doi.org/10.1016/S0140-6736(06)69074-0
2006
Winston A; Amin J; Marriott D; Mallon PW; Carr AD; Cooper DA; Emery S, 2006, 'Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy', HIV Medicine, vol. 7, pp. 105 - 111, http://dx.doi.org/10.1111/j.1468-1293.2006.00349.x
2006
Winston A; Amin J; Hales GP; Cooper DA; Emery S, 2006, 'Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced HIV-positive individuals', AIDS Research and Human Retroviruses, vol. 22, pp. 338 - 341, http://dx.doi.org/10.1089/aid.2006.22.338
2006
Puls R; Emery S, 2006, 'Therapeutic vaccination against HIV: current progress and future possibilities', Clinical Science, vol. 110, pp. 59 - 71, http://dx.doi.org/10.1042/CS20050157
2006
Kelleher AD; Puls R; Bebbington M; Boyle D; Kent S; Kippax SC; Purcell D; Thomson S; Wand HC; Cooper DA; Emery S; Ffrench RA, 2006, 'A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1', AIDS, vol. 20, pp. 294 - 297, http://dx.doi.org/10.1097/01.aids.0000199819.40079.e9
2006
Dwyer D; Workman C; Hales GP; Amin J; Cooper DA; Miller J; Emery S, 2006, 'Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: The ALLIANCE Study', Antiviral Therapy, vol. 11, pp. 409 - 419
2006
De Rose R; Sullivan MT; Dale CJ; Kelleher AD; Emery S; Cooper DA; Ramshaw I; Boyle D; Kent SJ, 2006, 'Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines.', Human Vaccines, vol. 2, pp. 134 - 136
2006
Lifson A; Rhame F; Belloso WH; Dragsted U; El-Sadr W; Gatell J; Hoy JF; Krum E; Nelson R; Pedersen C; Pett SL; Davey R, 2006, 'Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials', HIV Clinical Trials, vol. 7, pp. 125 - 141, http://dx.doi.org/10.1310/7MER-XFA7-1762-E2WR
2006
Hales GP; Birch C; Crowe S; Workman C; Hoy JF; Kelleher AD; Lincoln D; Lincoln D; Law MG; Emery S, 2006, 'A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: The CREST study.', PLoS Clinical Trials, vol. 1, pp. e18, http://dx.doi.org/10.1371/journal.pctr.0010018
2006
Mocroft A; Neaton JD; Bebchuk JD; Staszewski S; Antunes F; Knysz B; Law MG; Phillips AN; Lundgren JD, 2006, 'The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era', CLINICAL TRIALS, vol. 3, pp. 119 - 132, http://dx.doi.org/10.1191/1740774506cn138oa
2006
Emery S; Dwyer DE; McKinnon M, 2006, 'Epilogue: Preparing for an influenza pandernic in Australia', Medical Journal of Australia, vol. 185, pp. S80 - S80
2006
Samaras K; Wand HC; Law MG; Emery S; Cooper DA; Carr AD, 2006, 'Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition and metabolic parameters', Antiviral Therapy, vol. 11, pp. L23 - L24, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000241975800055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2006
El-Sadr W; Lundgren JD; Neaton JD; Gordin F; Abrams D; Arduino R; Babiker AG; Burman W; Clumeck N; Cohen C; Cohn D; Cooper DA; Darbyshire JH; Emery S; Fatkenheuer G; Gazzard B; Hoy JF; Klingman K; Losso MH; Markowitz N; Neuhaus J; Phillips A; Rappaport C, 2006, 'CD4+ count-guided interruption of antiretroviral treatment.', New England Journal of Medicine, vol. 355, pp. 2283 - 2296, http://dx.doi.org/10.1056/NEJMoa062360
2006
Harrod ME; Emery S; Dwyer DE, 2006, 'Antivirals in the management of an influenza pandemic', Medical Journal of Australia, vol. 185, pp. S58 - S61
2006
Pace C; Grady C; Wendler D; Bebchuk JD; Tavel JA; McNay LA; Forster HP; Killen J; Emanuel EJ, 2006, 'Post-trial access to tested interventions: The views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study', AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 22, pp. 837 - 841, http://dx.doi.org/10.1089/aid.2006.22.837
2006
Pace C; Emanuel EJ; Chuenyam T; Duncombe C; Bebchuk JD; Wendler D; Tavel JA; McNay LA; Phanuphak P; Forster HP; Grady C, 2005, 'The quality of informed consent in a clinical research study in Thailand.', IRB, vol. 27, pp. 9 - 17, https://www.ncbi.nlm.nih.gov/pubmed/15835065
2005
Kovacic JC; Martin A; Carey DL; Wand HC; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr AD, 2005, 'Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy', Antiviral Therapy, vol. 10, pp. 135 - 143
2005
Mallon PW; Unemori P; Sedwell R; Morey AL; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2005, 'In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA', Journal of Infectious Diseases, vol. 191, pp. 1686 - 1696, http://dx.doi.org/10.1086/429697
2005
Winston A; Bloch MT; Carr AD; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S, 2005, 'Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy', Journal of Antimicrobial Chemotherapy, vol. 56, pp. 380 - 387, http://dx.doi.org/10.1093/jac/dki235
2005
Winston A; Hales GP; Amin J; van Schaick E; Cooper DA; Emery S, 2005, 'The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals', AIDS, vol. 19, pp. 1393 - 1399, http://dx.doi.org/10.1097/01.aids.0000181009.77632.36
2005
Carey DL; Wand HC; Martin A; Rothwell S; Emery S; Cooper DA; Carr AD, 2005, 'Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial', AIDS, vol. 19, pp. 1325 - 1327, http://dx.doi.org/10.1097/01.aids.0000180106.11383.cc
2005
Winters B; Harrigan R; Montaner JS; Perez-Elias M; Miller M; Emery S; van Leth F; Robinson P; Baxter J; Gazzard B; Pozniak A; Castor D; Hammer S; Rinehart A; Bacheler L, 2005, 'Clinically relevant breakpoints for virco (R) TYPE HIV-1 phenotypic resistance information', Antiviral Therapy, vol. 10, pp. S39 - S39, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000231963100053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2005
Wand HC; Law MG; Emery S; Cooper DA; Carr AD, 2005, 'Increase in limb fat after nucleoside analogue cessation is not associated with decreased visceral fat and has different risk factors', Antiviral Therapy, vol. 10, pp. L5 - L5, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000235133100020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2005
Mallon PW; Wand HC; Law MG; Miller J; Cooper DA; Carr AD, 2005, 'Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia.', JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 38, pp. 156 - 162, http://dx.doi.org/10.1097/01.qai.0000147527.64863.1a
2005
Emery S; Workman C; Puls R; Bloch M; Baker D; Bodsworth NJ; Anderson JA; Crowe SM; Hoy JF; Aichelburg A; Ward LA; Boyle D; Law MG; Kelleher AD; Cooper DA, 2005, 'Randomised, Placebo-Controlled, Phase 1/2a Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon-y in HIV-1 Infected Subjects', Human Vaccines, vol. 1, pp. 232 - 238, http://dx.doi.org/10.4161/hv.1.6.2342
2005
Sabik L; Pace CA; Forster-Gertner HP; Wendler D; Bebchuk JD; Tavel JA; McNay LA; Killen J; Emanuel EJ; Grady C, 2005, 'Informed consent: Practices and views of investigators in a multinational clinical trial', IRB Ethics and Human Research, vol. 27, pp. 13 - 18
2005
Duncombe CJ; Kerr SJ; Ruxrungtham K; Dore GJ; Law MG; Emery S; Lange J; Phanuphak P; Cooper DA, 2005, 'HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting', AIDS, vol. 19, pp. 169 - 178, http://dx.doi.org/10.1097/00002030-200501280-00009
2005
Arduino R; Nannini E; Rodriguez-Barradas M; Schrader S; Losso MH; Ruxrungtham K; Allende MC; Emery S; Fosdick L; Neaton JD; Tavel JA; Davey R; Lane HC, 2004, 'CD4 cell response to 3 doses of subcutaneous interleukin 2:Meta-analysis of 3 Vanguard studies', Clinical Infectious Diseases, vol. 39, pp. 115 - 122, http://dx.doi.org/10.1086/421775
2004
Dale C; De Rose R; Wilson K; Croom H; Thomson S; Coupar B; Ramsay AJ; Purcell D; Ffrench R; Law MG; Emery S; Cooper DA; Ramshaw I; Boyle D; Kent S, 2004, 'Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN[gamma] or IL-12', Vaccine, vol. 23, pp. 188 - 197, http://dx.doi.org/10.1016/j.vaccine.2004.05.024
2004
Ungsedhapand C; Srasuebkul P; Cardiello P; Ruxrungtham K; Ratanasuwan W; Kroon E; Tongtalung M; Juengprasert N; Ubolyam S; Siangphoe U; Emery S; Lange JM; Cooper DA; Phanuphak P, 2004, 'Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection', JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 36, pp. 693 - 701, http://dx.doi.org/10.1097/00126334-200406010-00006
2004
Mallon PW; Sedwell R; Unemori P; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2004, 'Changes in nuclear gene expression resulting from NRTI-induced inhibition of mitochondrial transcription reveal links between mitochondrial dysfunction and lipid metabolism', Antiviral Therapy, vol. 9, pp. L56 - L56, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000231616000125&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2004
Mallon PW; Unemori P; Sedwell R; Morey AL; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2004, 'In vivo nucleoside reverse transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes independent to HIV infection', Antiviral Therapy, vol. 9, pp. L11 - L11, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000231616000044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2004
Pett SL; Williams LA; Day RO; Lloyd AR; Carr AD; Clezy KR; Emery S; Kaplan E; Mcphee D; Mclachlan AJ; Gelder F; Lewin S; Liauw WS; Williams KM, 2004, 'A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals', HIV Clinical Trials, vol. 5, pp. 91 - 98, http://dx.doi.org/10.1310/1FLN-8KFC-5HEQ-K19J
2004
Carey DL; Workman C; Rogers GJ; Baker DA; Martin A; Wand HC; Emery S; Cooper DA; Carr AD, 2004, 'Rosiglitazone for HIV lipoatrophy: 84 weeks follow-up', Antiviral Therapy, vol. 9, pp. L46 - L46, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000231616000106&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2004
Carr AD; Workman C; Carey DL; Rogers GJ; Martin A; Baker DA; Wand HC; Law MG; Samaras K; Emery S; Cooper DA, 2004, 'No effect of rosiglitazone for treatment of HIV-1 lipoatrophy:randomised, double-blind, placebo-controlled trial', Lancet, vol. 363, pp. 429 - 438, http://dx.doi.org/10.1016/S0140-6736(04)15489-5
2004
Martin A; Smith DE; Carr AD; Ringland C; Amin J; Emery S; Hoy JF; Workman C; Doong N; Freund J; Cooper DA, 2004, 'Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study', AIDS, vol. 18, pp. 1029 - 1036, http://dx.doi.org/10.1097/00002030-200404300-00011
2004
Ioannidis JP; Trikalinos TA; Law MG; Carr AD, 2003, 'HIV lipodystrophy case definition using artificial neural network modelling.', Antiviral Therapy, vol. 8, pp. 435 - 441
2003
Law MG; Emery S, 2003, 'Selective exclusion of treatment arms in multi-arm randomized clinical trials', Statistics in Medicine, vol. 22, pp. 19 - 30, http://dx.doi.org/10.1002/sim.1308
2003
Clegg AO; Williamson P; Biti RA; Cooper DA; Emery S; Carr AD; Stewart GJ, 2003, 'Chemokine receptor genotype and response to interleukin-2 therapy in HIB-1-infected individuals', Clinical Immunology, vol. 106, pp. 36 - 40, http://dx.doi.org/10.1016/S1521-6616(02)00020-7
2003
Carr AD; Emery S; Law MG; Puls R; Lundgren JD; Powderly W, 2003, 'An objective case definition of lipodystrophy in HIV-infected adults: a case-control study', Lancet, vol. 361, pp. 726 - 735, http://dx.doi.org/10.1016/S0140-6736(03)12656-6
2003
Carr AD; Law MG, 2003, 'An objective lipodystrophy severity grading scale using the lipodystrophy case definition score', Journal of Acquired Immune Deficiency Syndrome, vol. 33, pp. 571 - 576, http://dx.doi.org/10.1097/00126334-200308150-00004
2003
Amin J; Moore A; Carr AD; French MA; Law MG; Emery S; Cooper DA, 2003, 'Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2', HIV Clinical Trials, vol. 4, pp. 252 - 261, http://dx.doi.org/10.1310/K2U9-QC2V-1Y3V-5DYF
2003
Birch C; Middleton T; Hales GP; Cooper DA; Law MG; Crowe S; Hoy JF; Emery S, 2003, 'Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testing', Journal of Acquired Immune Deficiency Syndrome, vol. 32, pp. 57 - 61, http://dx.doi.org/10.1097/00126334-200301010-00008
2003
Miller J; Carr AD; Emery S; Law MG; Mallal SS; Baker D; Smith DG; Kaldor JM; Cooper DA, 2003, 'HIV lipodystrophy: prevalence, severity and correlates of risk in Australia', HIV Medicine, vol. 4, pp. 293 - 301, http://dx.doi.org/10.1046/j.1468-1293.2003.00159.x
2003
Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P, 2003, 'Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors', AIDS, vol. 17, pp. 1889 - 1896, http://dx.doi.org/10.1097/00002030-200309050-00007
2003
Sayer DC; Land S; Gizzarelli L; French M; Hales G; Emery S; Christiansen FT; Dax EM; Dunne M; Crowe S; Birch C; Middleton T; Saksena N; Bryson G; Salem H; Cunningham P; Suzuki K; Schroeder B; Rawlings L; Higgins G; Chuah J; Roth N; Barnes T; Mills G; Daye J; Watson J, 2003, 'Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations', Journal of Clinical Microbiology, vol. 41, pp. 227 - 236, http://dx.doi.org/10.1128/JCM.41.1.227-236.2003
2003
McNay LA; Tavel JA; Oseekey K; McDermott CM; Mollerup D; Bebchuk JD, 2002, 'Regulatory approvals in a large multinational clinical trial: the ESPRIT experience', CONTROLLED CLINICAL TRIALS, vol. 23, pp. 59 - 66, http://dx.doi.org/10.1016/S0197-2456(01)00183-0
2002
Emery S; Birch C; Crowe S; Hoy J; Workman C; Kelleher T; McKenna P; Cooper D; Lincoln D; Hales G; Law M, 2002, 'CREST - A randomised comparison of two resistance test platforms: genotype and genotype plus VirtualPhenotype (TM): interim results', ANTIVIRAL THERAPY, vol. 7, pp. S152 - S152, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000177401300141&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2002
Emery S; Abrams D; Cooper DA; Darbyshire JH; Lane HC; Lundgren JD; Neaton JD, 2002, 'The evaluation of subcutaneous proleukin® (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials', Control Clin Trials, vol. 23, pp. 198 - 220, http://dx.doi.org/10.1016/S0197-2456(01)00179-9
2002
Emery S; Cooper DA, 2002, 'HIV medicine', Medical Journal of Australia, vol. 176, pp. 21 - 21
2002
French MA; Amin J; Roth N; Law MG; Emery S; Drummond F, 2002, 'Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: The OzCombo 2 Study', HIV Clinical Trials, vol. 3, pp. 177 - 185, http://dx.doi.org/10.1310/9N21-1HG1-7N1Q-JKW1
2002
Babiker AG; Darbyshire JH; Cooper DA; Hooker MH; Withnall R; Yeni P; Angarano G; Antunes F; Churchill D; Conway B; Flepp M; Lelekis M; Gatell J; Girard PM; Hemmer R; Lundgren J; Mijch A; Mulcahy F; Ristola M; Salzberger B; Sandström E; Staszewski S; Weber J; De Wit S; Aboulker JP; Emery S; Floridia M; Gartland M; Manion D; Popescu M; Schnittman S; Stek M; Verbiest W; Flandre P; Law M; Schade-Brittinger C; Walker S; Bucciardini R; Boukli N; Carey D; Gargalianos P; Mollerup D; Brun-Vezinet F; Loveday C; Seligmann M, 2001, 'An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: Design, rationale, and methods of the initio trial', Controlled Clinical Trials, vol. 22, pp. 160 - 175, http://dx.doi.org/10.1016/S0197-2456(00)00123-9
2001
Tavel JA; Fosdick L, 2001, 'Closeout of four phase II Vanguard trials and patient rollover into a large international phase III HIV clinical endpoint trial', Controlled Clinical Trials, vol. 22, pp. 42 - 48, http://dx.doi.org/10.1016/S0197-2456(00)00114-8
2001
Emery S; Lane HC; Neaton JD, 2001, 'Interleukin-2 in clinical trials: Other factors to be considered - Reply', JOURNAL OF INFECTIOUS DISEASES, vol. 183, pp. 680 - 680, http://dx.doi.org/10.1086/318546
2001
Pett SL; Emery S, 2001, 'Immunomodulators as adjunctive therapy for HIV-1 infection', Journal of Clinical Virology, vol. 22, pp. 289 - 295, http://dx.doi.org/10.1016/S1386-6532(01)00201-3
2001
Nannini EC, 2001, 'Interleukin-2 in clinical trials: Other factors to be considered (multiple letters)', Journal of Infectious Diseases, vol. 183, pp. 679 - 680, http://dx.doi.org/10.1086/318544
2001
Clezy KR; Emery S, 2000, 'Clinical trials of antiretroviral therapy in developing countries', Australian and New Zealand Journal of Medicine, vol. 30, pp. 3 - 4, http://dx.doi.org/10.1111/j.1445-5994.2000.tb01045.x
2000
Losso MH; Belloso WH; Emery S, 2000, 'A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4(+) cell counts >= 350/mm(3) (vol 181, pg 1614, 2000)', JOURNAL OF INFECTIOUS DISEASES, vol. 181, pp. 2122 - 2122, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000087923900051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2000
Carr AD; Chuah J; Hudson J; French MA; Hoy JF; Law MG; Sayer D; Emery S; Cooper DA; On BOTC, 2000, 'A randomised, open-label comparison of three highly active antiretroviral therapy regimes including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study', AIDS, vol. 14, pp. 1171 - 1180, http://dx.doi.org/10.1097/00002030-200006160-00014
2000
Emery S; Capra WB; Cooper DA; Mitsuyasu RT; Kovacs JA; Vig P; Smolskis M; Saravolatz LD; Lane HC; Fyfe G; Curtin PT; For TII, 2000, 'Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease', Journal of Infectious Diseases, vol. 182, pp. 428 - 434, http://dx.doi.org/10.1086/315736
2000
Losso MH; Belloso WH; Emery S; Benetucci JA; Cahn PE; Lasala MC; Lopardo G; Salomon H; Saracco M; Nelson E; Law MG; Davey RC; Allende MC; Lane HC; And TVSG, 2000, 'A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts ? 350/mm³', Journal of Infectious Diseases, vol. 181, pp. 1614 - 1621, http://dx.doi.org/10.1086/315430
2000
Losso MH; Belloso WH; Emery S, 2000, 'Erratum: A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts ≥350/mm3 (Journal of Infectious Diseases (May 2000) 181 (1614-1621))', Journal of Infectious Diseases, vol. 181, pp. 2122, http://dx.doi.org/10.1086/315531
2000
Ruxrungtham K; Suwanagool S; Tavel JA; Chuenyam M; Kroon E; Ubolyam S; Buranapraditkun S; Techasathit W; Li Y; Emery S; Davey RC; Fosdick L; Kunanusont C; Lane HC; Phanuphak P; And TVSG, 2000, 'A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand', AIDS, vol. 14, pp. 2509 - 2513, http://dx.doi.org/10.1097/00002030-200011100-00013
2000
Mills J; Carr AD; Smith DE; Emery S; Law MG; Grey PA; Cooper DA, 2000, 'Lipodystrophy following antiretroviral therapy of primary HIV infection (letter)', AIDS, vol. 14, pp. 2406 - 2407, http://dx.doi.org/10.1097/00002030-200010200-00025
2000
Cooper DA; Emery S, 1999, 'Latent reservoirs of HIV infection: Flushing with IL-2?', Nature Medicine, vol. 5, pp. 611 - 612, http://dx.doi.org/10.1038/9454
1999
Cooper DA; Emery S, 1998, 'Therapeutic strategies for HIV infection - time to think hard. (Editorial)', New England Journal of Medicine, vol. 339, pp. 1319 - 1321, http://dx.doi.org/10.1056/NEJM199810293391810
1998
Carr AD; Emery S; Lloyd AR; Hoy JF; Garsia R; French MA; Stewart GA; Fyfe G; Cooper DA, 1998, 'Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, milticenter study', Journal of Infectious Diseases, vol. 178, pp. 992 - 999, http://dx.doi.org/10.1086/515653
1998
Kelleher AD; Roggensack M; Emery S; Carr AD; French MA; Cooper DA, 1998, 'Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens', Clinical and Experimental Immunology, vol. 113, pp. 85 - 91, http://dx.doi.org/10.1046/j.1365-2249.1998.00633.x
1998
Emery S; Cooper DA, 1997, 'Drug companies have a duty to continue treatment', British Medical Journal: Clinical Research, vol. 314, pp. 889 - 889
1997
Kelleher S; Emery S; Cunningham PH; Duncombe CJ; Carr AD; Golding H; Forde S; Hudson J; Roggensack M; Forrest BD; Cooper DA, 1997, 'Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection', AIDS Research and Human Retroviruses, vol. 13, pp. 29 - 32, http://dx.doi.org/10.1089/aid.1997.13.29
1997
Emery S; Lane HC, 1997, 'Immune reconstitution in HIV infection', Current Opinion in Immunology, vol. 9, pp. 568 - 572, http://dx.doi.org/10.1016/S0952-7915(97)80112-4
1997
Emery S; Lane HC, 1996, 'Immune-based therapies in HIV infection: recent developments.', AIDS (London, England), vol. 10 Suppl A
1996
Schooley RT; Ramirez-Ronda C; Lange JM; Cooper DA; Lavelle J; Lefkowitz L; Moore MW; Larder BA; St Clair M; Mulder JW; Mckinnis R; Pennington KN; Harrigan PR; Kinghorn I; Steel H; Rooney J, 1996, 'Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy', Journal of Infectious Diseases, vol. 173, pp. 1354 - 1366, http://dx.doi.org/10.1093/infdis/173.6.1354
1996
Carr AD; Emery S; Kelleher AD; Law MG; Cooper DA, 1996, 'CD8+ lymphocyte responses to antiretroviral therapy of HIV infection', Journal of acquired immune deficiency syndrome and human retrovirology, vol. 13, pp. 320 - 326, http://dx.doi.org/10.1097/00042560-199612010-00004
1996
Emery S; Lane HC, 1996, 'Immune-based therapies in HIV infection', AIDS, vol. 10, pp. S159 - 164, http://dx.doi.org/10.1097/00002030-199601001-00022
1996
Dax EM; Best SJ, 1996, 'If it's the virus why aren't we measuring it? [3]', Medical Journal of Australia, vol. 165, pp. 119
1996
Emery S; Carr A; Cooper DA, 1995, 'If it's the virus, why aren't we measuring it?', The Medical journal of Australia, vol. 163, pp. 508 - 509
1995
Emery S; Cooper DA, 1995, 'Antiretro viral therapy of human immunodeficiency virus type‐1 (HIV‐1) infection', Australian and New Zealand Journal of Medicine, vol. 25, pp. 344 - 349, http://dx.doi.org/10.1111/j.1445-5994.1995.tb01900.x
1995
Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; Gonzalez-Lahoz J; Stevens JW; Fiddian AP, 1993, 'Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic Millimeter', New England Journal of Medicine, vol. 329, pp. 297 - 303, http://dx.doi.org/10.1056/NEJM199307293290501
1993
Slater TF; Cheeseman KH; Benedetto C; Collins M; Emery S; Maddix SP; Nodes JT; Proudfoot K; Burton GW; Ingold KU, 1990, 'Studies on the hyperplasia ('regeneration') of the rat liver following partial hepatectomy. Changes in lipid peroxidation and general biochemical aspects', Biochemical Journal, vol. 265, pp. 51 - 59, http://dx.doi.org/10.1042/bj2650051
1990
Cheeseman KH; Emery S; Maddix SP; Slater TF; Burton GW; Ingold KU, 1988, 'Studies on lipid peroxidation in normal and tumour tissues. The Yoshida rat liver tumour', Biochemical Journal, vol. 250, pp. 247 - 252, http://dx.doi.org/10.1042/bj2500247
1988
Cheeseman KH; Davies MJ; Emery S; Maddix SP; Slater TF, 1987, 'Effects of αtocopherol on carbon tetrachloride metabolism in rat liver microsomes', Free Radical Research, vol. 3, pp. 325 - 330, http://dx.doi.org/10.3109/10715768709069800
1987
Emery S; Oldham HG; Norman SJ; Chenery RJ, 1985, 'The effect of cimetidine and ranitidine on paracetamol glucuronidation and sulphation in cultured rat hepatocytes', Biochemical Pharmacology, vol. 34, pp. 1415 - 1421, http://dx.doi.org/10.1016/0006-2952(85)90678-1
1985
Conference Papers
add
Kunisaki KM; Niewoehner DE; Collins G; Aagaard B; Atako NB; Bakowska E; Clarke A; Corbelli GM; Ekong E; Emery S; Finley EB; Florence E; Infante RM; Kityo CM; Madero JS; Nixon DE; Tedaldi E; Vestbo J; Wood R; Connett JE, 2018, 'Pulmonary Effects of Immediate Versus Deferred Antriretroviral Treatment Initiation: Final Follow-Up Results from the Randomized Strategic Timing of Antiretroviral Treatment (START) Pulmonary Substudy', in AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, AMER THORACIC SOC, San Diego, CA, presented at International Conference of the American-Thoracic-Society, San Diego, CA, 18 May 2018 - 23 May 2018, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449980302552&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2018
Rodger A; Lampe F; Burman W; Gruhlich A; Friedland G; El-Sadr W; Neaton J; Emery S; Corbelli G; Molina JM; Orkin C; Gatell J; Gerstoft J; Ruxrungtham K; de Souza MB; Phillips A, 2016, 'Assessment of the impact of early ART on sexual behaviour in INSIGHT strategic timing of antiretroviral treatment (START) trial', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000395394300243&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2016
Wines BD; Vanderven HA; Esparon S; Madhavi V; Center RJ; Kristensen AB; Gonelli CA; Poumbourios A; Parsons M; Emery S; Kelleher A; Purcell DFJ; Kent SJ; Hogarth PM, 2016, 'Fc gamma R ectodomain probes measure anti-viral IgG effector function', in EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY-BLACKWELL, Melbourne, AUSTRALIA, pp. 1256 - 1257, presented at International Congress of Immunology (ICI), Melbourne, AUSTRALIA, 21 August 2016 - 26 August 2016, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000391563600040&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2016
Madhavi V; Wines B; Emery S; Amin J; Kelleher A; Hogarth M; Stratov I; Kent S, 2016, '"HIV-1 controllers" - what's their secret?', in EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY-BLACKWELL, Melbourne, AUSTRALIA, pp. 74 - 74, presented at International Congress of Immunology (ICI), Melbourne, AUSTRALIA, 21 August 2016 - 26 August 2016, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000383610400148&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2016
Achhra AC; Phillips AN; Emery S; MacArthur RD; Furrer H; De Wit S; Losso MH; Law MG, 2015, 'PRE-THERAPY INFLAMMATION/COAGULATION ACTIVATION AND LONG-TERM CD4 RESPONSE TO ANTIRETROVIRAL THERAPY', in SEXUALLY TRANSMITTED INFECTIONS, BMJ PUBLISHING GROUP, pp. A73 - A73, http://dx.doi.org/10.1136/sextrans-2015-052270.195
2015
Land S; Tu E; Swenson L; Kelleher A; Kaye S; Pett SL; Emery S; Kaiser R; Silk D; Berthon-Jones N; Harrigan PR, 2013, 'Proviral DNA testing of HIV tropism in the Maraviroc Switch Collaborative Study (MARCH) - results of a three-phase quality assurance (QA) programme', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Toronto, CANADA, pp. A144 - A144, presented at International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Toronto, CANADA, 04 June 2013 - 08 June 2013, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335229500117&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2013
Larder BA; Revell AD; Wang D; Hamers R; Tempelman H; Barth R; Wensing AMJ; Morrow C; Wood R; van Sighem A; Reiss P; Nelson M; Emery S; Montaner JM; Lane HC, 2013, 'Accurate prediction of response to HIV therapy without a genotype: a potential tool for therapy optimization in resource-limited settings', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Toronto, CANADA, pp. A20 - A20, presented at International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Toronto, CANADA, 04 June 2013 - 08 June 2013, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335229500016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2013
Ebeling PR; Haskelberg H; Hoy J; Amin J; Emery S; Carr A, 2011, 'LOWER FAT MASS AND LOWER BONE FORMATION PREDICT GREATER BONE LOSS WITH TENOFOVIR IN HIV-INFECTED ADULTS', in OSTEOPOROSIS INTERNATIONAL, SPRINGER LONDON LTD, Gold Coast, AUSTRALIA, pp. S614 - S615, presented at IOF Regionals 2nd Asia-Pacific Osteoporosis and Bone Meeting / ANZBMS Annual Scientific Meeting held with the JSBMR, Gold Coast, AUSTRALIA, 04 September 2011 - 08 September 2011, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000309258200234&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2011
Larder BA; Wang D; Revell AD; Emery S; De Wolf F; Nelson M; Perez Elias MJ; Harrigan PR; Montaner JS, 2010, 'The development of computational models that accurately predict virological response to HIV therapy to power an online treatment selection tool', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Dubrovnik, CROATIA, pp. A89 - A89, presented at International HIV and Hepatitis Virus Drug Resistance and Curative Strategies Workshop, Dubrovnik, CROATIA, 08 June 2010 - 12 June 2010, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000280215800091&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2010
Larder BA; Wang D; Revell AD; Emery S; De Wolf F; Nelson M; Perez Elias MJ; Harrigan PR; Montaner JS, 2010, 'The development of computational models that accurately predict virological response to HIV therapy to power an online treatment selection tool', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Dubrovnik, CROATIA, pp. A89 - A89, presented at Workshop on International HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Dubrovnik, CROATIA, 08 July 2010 - 12 July 2010, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431300076&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2010
Bloch M; Martin A; Amin J; Emery S; Carr A; Baker D; Cooper DA, 2010, 'Predictors of limb fat changes in patients switched to tenofovir-emtricitabine or abacavir-lamivudine', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, London, ENGLAND, pp. A7 - A7, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, London, ENGLAND, 04 November 2010 - 06 November 2010, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431200022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2010
Bloch M; Martin A; Amin I; Emery S; Carr A; Baker D; Cooper DA, 2010, 'Predictors of limb fat changes in patients switched to tenofovir-emtricitabine or abacavir-lamivudine', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, London, ENGLAND, pp. A7 - A7, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, London, ENGLAND, 04 November 2010 - 06 November 2010, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431500008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2010
Revell AD; Wang D; Harrigan R; Gatell J; Ruiz L; Emery S; Perez-Elias MJ; Torti C; Baxter J; DeWolf F; Gazzard B; Geretti AM; Staszewski S; Hamers R; Wensing AMJ; Lange J; Montaner JM; Larder BA, 2009, 'Computational models developed without a genotype for resource-poor countries predict response to HIV treatment with 82% accuracy', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Ft Myers, FL, pp. A38 - A38, presented at 18th International HIV Drug Resistance Workshop, Ft Myers, FL, 09 June 2009 - 13 June 2009, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000268039900053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2009
Puls RL; Srasuebkul P; Petoumenos K; Emery S; Cooper DA, 2009, 'Anthropometric and metabolic outcomes in a 48-week randomized, open-label study of three different combination antiretroviral regimens as initial therapy for HIV infection', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Philadelphia, PA, pp. A8 - A9, presented at 11th International Workshop on AdverseDrug Reactions and Co-Morbidities in HIV, Philadelphia, PA, 26 October 2009 - 28 October 2009, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000272060000026&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2009
Carey D; Amin J; Emery S, 2009, 'Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir in randomized trials: systematic review and meta-analysis', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Philadelphia, PA, pp. A58 - A58, presented at 11th International Workshop on AdverseDrug Reactions and Co-Morbidities in HIV, Philadelphia, PA, 26 October 2009 - 28 October 2009, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000272060000079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2009
Buchbinder SP; Mehrotra DV; Duerr A; Fitzgerald DW; Mogg R; Li D; Gilbert PB; Lama JR; Marmor M; del Rio C; McElrath MJ; Casimiro DR; Gottesdiener KM; Chodakewitz JA; Corey L; Robertson MN, 2008, 'Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial', in The Lancet, pp. 1881 - 1893, http://dx.doi.org/10.1016/S0140-6736(08)61591-3
2008
Samaras K; Wand H; Law M; Emery S; Cooper DA; Carr A, 2006, 'Metabolic syndrome in HIV-infected patients using IDF and ATPIII criteria: prevalence, discordance and clinical utility', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, San Francisco, CA, pp. L4 - L4, presented at 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Francisco, CA, 24 September 2006 - 26 September 2006, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000241975800023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2006
Wand H; Calmy A; Carey D; Samaras K; Carr A; Law M; Cooper D; Emery S, 2006, 'Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV-infected adults', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, San Francisco, CA, pp. L4 - L4, presented at 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Francisco, CA, 24 September 2006 - 26 September 2006, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000241975800024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2006
Winters B; Harrigan R; Montaner J; Perez-Elias M; Millers M; Emery S; van Leth F; Robinson P; Baxter JD; Gazzard B; Pozniak A; Castor D; Hammer S; Rinehart A; Bacheler L, 2005, 'Clinically relevant breakpoints for virco (R) TYPE HIV-1 phenotypic resistance information', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Quebec City, CANADA, pp. S39 - S39, presented at 14th International HIV Drug Resistance Workshop, Quebec City, CANADA, 07 June 2005 - 11 June 2005, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000232470800040&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2005
Bacheler LT; Winters B; Nauwelaers D; Rinehart A; McGregor M; Harrigan R; Perez-Elias M; Miller M; Emery S; van Leth F; Robinson P; Baxter JD; Pozniak A, 2004, 'Estimation of phenotypic clinical cutoffs for VirtualPhenotype (TM) through meta analyses of clinical trial and cohort data', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Tenerife, SPAIN, pp. U108 - U109, presented at 13th International HIV Drug Resistance Workshop, Tenerife, SPAIN, 08 June 2004 - 12 June 2004
2004
Winters B; Bacheler LT; Nauwelaers D; Rinehart A; McGregor M; Harrigan R; Perez-Elias M; Miller M; Emery S; van Leth F; Hall D; Baxter JD; Pozniak A, 2004, 'Evaluation of different approaches for the definition of clinically relevant breakpoints for phenotypic resistance data', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Tenerife, SPAIN, pp. U92 - U92, presented at 13th International HIV Drug Resistance Workshop, Tenerife, SPAIN, 08 June 2004 - 12 June 2004
2004
Puls R; Munier M; MCgHIE K; Chadborn I; Emery S; Kelleher AD; Law MG; Carr AD, 2003, 'Impact of adiponectin, C-reactive protein and leptin on the HIV lipodystrophy case definition', in Antiviral Therapy, Int Medical Press Ltd, Paris, FRANCE, pp. L73 - L73, presented at 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris, FRANCE, 08 July 2003 - 11 July 2003, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000231266500130&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2003
Puls R; Munier M; MCgHIE K; Chadborn I; Emery S; Kelleher AD; Law MG; Carr AD, 2003, 'HIV Lipodystrophy Case Definition Study Group. Impact of adiponectin, C-reactive protein and leptin on the HIV lipodystrophy case definition', in Antiviral Therapy, Int Medical Press Ltd, pp. 57 - 57
2003
Amin J; Carr A; Hill A; Emery S; Law M; Cooper DA, 2002, 'Haematological changes in patients randomized to HAART regimens containing either zidovudine or stavudine', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, SAN DIEGO, CALIFORNIA, pp. L60 - L60, presented at 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, SAN DIEGO, CALIFORNIA, 22 September 2002 - 25 September 2002, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000179501500101&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2002
Pantaleo G, 1999, 'Immune reconstitution in HIV infection', in AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT INC PUBL, pp. 1600 - 1600, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000084146700005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1999
Losso M; Belloso W; Benetucci J; Cahn P; Lasala MB; Lopardo G; Clara L; Allende M; Emery S; Davey R; Lane HC, 1998, 'A phase II study of subcutaneous (SC) IL-2 plus antiretrovirals (ARV) vs ARV alone in patients with HIV infection and CD4+ cell count >= 350/MM3.', in AIDS, LIPPINCOTT WILLIAMS & WILKINS, pp. S65 - S65
1998
SLATER TF; CHEESEMAN KH; CARRIE ML; LI L; CLUTTON S; NIGAM S; EMERY S; INGOLD KU, 1993, 'DISTURBANCES OF LIPID-PEROXIDATION IN RAT-LIVER CANCER-CELLS AND IN NORMAL REGENERATING RAT-LIVER', in Nigam S; Honn KV; Marnett LJ; Walden TL (eds.), EICOSANOIDS AND OTHER BIOACTIVE LIPIDS IN CANCER, INFLAMMATION AND RADIATION-INJURY, KLUWER ACADEMIC PUBLISHERS, FREE UNIV BERLIN, UNIVESSITATSKLINIKUM STEGITZ, BERLIN, GERMANY, pp. 81 - 88, presented at 2ND INTERNATIONAL CONF ON EICOSANOIDS AND OTHER BIOACTIVE LIPIDS IN CANCER, INFLAMMATION AND RADIATION INJURY, FREE UNIV BERLIN, UNIVESSITATSKLINIKUM STEGITZ, BERLIN, GERMANY, 17 September 1991 - 21 September 1991
1993
CHEESEMAN KH; EMERY S; MADDIX SP; PROUDFOOT K; BURTON GW; INGOLD KU; SLATER TF, 1989, 'LIPID-PEROXIDATION IN LIVER-TUMORS AND REGENERATING LIVER', in POLI G; CHEESEMAN KH; DIANZANI MU; SLATER TF (eds.), FREE RADICALS IN THE PATHOGENESIS OF LIVER INJURY, PERGAMON PRESS LTD, TURIN, ITALY, pp. 165 - 175, presented at 2ND CONGRESS ON FREE RADICALS IN LIVER INJURY, TURIN, ITALY, 09 June 1988 - 11 June 1988
1989
Conference Abstracts
add
Bunupuradah T; Kiertiburanakul S; Avihingsanon A; Chetchotisakd P; Techapornroong M; Leerattanapetch N; Kantipong P; Bowonwatanuwong C; Banchongkit S; Klinbuayaem V; Mekviwattanawan S; Nimitvilai S; Jirajariyavej S; Prasithsirikul W; Munsakul W; Bhakeecheep S; Chaivooth S; Phanuphak P; Cooper DA; Apornpong T; Kerr SJ; Emery S; Ruxrungtham K, 2015, 'Atazanavir/ritonavir 200/100 mg is non-inferior to atazanavir/ritonavir 300/100 mg in virologic suppressed HIV-infected Thai adults: a multicentre, randomized, open-label trial: LASA', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, Vol. 18, http://dx.doi.org/10.7448/IAS.18.5.20356
2015
Danta M; Zaunders J; Bailey MR; Marks K; Seddiki N; Emery S; Murray JM; Cooper DA; Koelsch K; Kelleher AD, 2012, 'Primary HIV-1 infection (PHI) is associated with reduced CD4 cell counts in terminal ileum biopsies, but not other gut biopsy sites', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, Vol. 27, pp. 19 - 19, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000308642600039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2012
Book Chapters
add
Emery S, 2013, 'Lipid Peroxidation, Antioxidants and Regenerating Rat Liver', in Nigram SK (ed.), Eicosanoids, Lipid Peroxidation and Cancer, Springer Science & Business Media, pp. 195 - 202
2013
Pett SL; Emery S; Cooper DA, 2006, 'Initial treatment of HIV-1 infection. Online access: www.antimicrobe.org', in Singh N; Swindells S; Shafer R (ed.), HIV Clinical Manual, edn. Original, ESun Technologies, LLC, online
2006
Ramacciotti TP; Smith DE; Emery S; Kelleher AD; Cooper DA, 2005, 'Therapeutic vaccination in PHI', in Jenssen H; Jager H (ed.), Primary HIV Infection ? Pathology, Diagnosis, Management, edn. Original, Thieme, Stuttgart, pp. 48 - 63
2005
Reports
add
Tu E; Swenson LC; Land S; Pett S; Emery S; Marks K; Kelleher AD; Kaye S; Kaiser R; Schuelter E; Harrigan R, 2013, Reply to "issues on results of the external quality assessment for proviral DNA testing of HIV-1 tropism in the maraviroc switch collaborative study", http://dx.doi.org/10.1128/JCM.02207-13
2013

Clinical research in HIV medicine, free radicals, antioxidants, Antiretroviral therapy, clinical trials, drug development, HIV.